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Summary
Crystallization is one of the most important downstream processing steps of ac-
tive pharmaceutical ingredients (APIs), signified by the fact that ∼90 % of all
APIs are formulated as crystals. The outcome of crystallization is ideally a pop-
ulation of uniform particles of the desired crystalline form and a favorable habit
that facilitates subsequent solid formulation steps. However, currently available
API crystallization processes often fail to achieve this goal and require several
energy-intensive and time consuming intermediate processing steps. Moreover,
the recent industrial, regulatory and academic push for sustainability created a
great need for new crystallization processes that facilitate intensified manufac-
turing. Emulsion-based crystallization techniques to produce spherical agglom-
erates (SAs) of API crystals are of great interest due to the favorable downstream
processing properties of the particles produced by these methods. Still, the util-
ity of emulsion-based crystallization is limited by the fact that it is typically
performed in batch tanks, resulting in a polydisperse population of particles and
a lack of knowledge regarding the formation mechanism of the individual SAs.
While microfluidic devices are well known to be capable of generating monodis-
perse emulsions of various morphologies and compositions, their application to
emulsion-based API crystallization has yet to be explored.
Work presented in this thesis brings together emulsion-based crystallization
and droplet microfluidics to develop a scalable, continuous API crystalliza-
tion platform that robustly produces SAs of unprecedented uniformity. First,
an overview of the existing body of relevant literature is given in Chapter 1.
Subsequently, in Chapter 2 a semi-batch spherical crystallization platform is
presented. This platform coupled monodisperse microfluidic emulsion gener-
ation with off-chip thin-film evaporation to produce uniform SAs of glycine, a
model API molecule. On-line microscopic monitoring of the crystallization pro-
xiii
cess enables the delineation of the distinct phases of SA formation: shrinkage,
stochastic nucleation, spherulitic growth and agglomerate aging. Next, Chap-
ter 3 presents experimental studies and mathematical modeling to determine
the effect of operating conditions on the morphological outcome of a thin-film
spherical crystallization process. It is found that droplets must first shrink to a
critical size before nucleation occurs to form complete SAs, whereas the oppo-
site leads to the formation of incomplete agglomerates or single crystals. In-
sights gained in this study provide valuable guidelines for the design of similar
processes in the future. A proof of concept continuous thin-film evaporator to
complement continuous microfluidic emulsion-generation is presented in Chap-
ter 4. This apparatus is capable of producing ∼1-10 g/day of high quality SAs
with a volumetric footprint of only ∼10 L, and can straightforwardly be scaled
up to industrially relevant production rates by parallelization. Finally, Chapter
5 summarizes the future outlook of this platform: an example of a newly devel-
oped advanced formulation technique for hydrophobic compounds is discussed




1.1 The Backdrop: Sustainable Manufacturing
In a broader context, this thesis addresses a gradually arising, yet urgent
issue, the strive for sustainability in pharmaceutical manufacturing, both in the
environmental and the economic sense. Sustainability in the context of the phar-
maceutical industry manifests itself in ”green chemistry” and ”green engineer-
ing” principles, and essentially refers to choosing the process with the lowest
possible economic and environmental footprint (i.e. the one that requires less
raw materials - including energy - and produces less hazardous waste) [1]–[3].
The emergence of this push for sustainable manufacturing is the natural conse-
quence of rising drug development costs [4]. Since product development - which
includes the manufacturing process - can account for as much as 35% of drug
development costs [5], streamlining manufacturing processes could save both
financial and environmental resources. This is especially true if one considers
that due to the unique characteristics of pharmaceutical process development -
the goal is to get a marketable product in the smallest possible time frame, as
opposed to robust, long-term manufacturing solutions [5], [6] - advances have
been lagging behind other industries. So much so, that a 2003 article in the
Wall Street Journal mocked drug manufacturing for being less advanced than
the processes for making potato chips and laundry detergents [7], and a 2004
white paper released by the FDA called for a shift from ”art-based” empirical
methods to rigorous, science-based process development [8]. Having realized
that conventional processes and empirical process development methods have
reached their limits, both academia and industry started looking for more ad-
vanced options [9].
Recent developments spawned by these efforts include the emergence of ra-
tional design approaches aided by advanced process analytical techniques [10],
[11] and a massive push for process intensification - in which the footprint of a
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given process is dramatically reduced while retaining the original output [12].
Two emerging technological solutions for process intensification, continuous
manufacturing and microreactors are at the forefront of these recent advances,
culminating in an end-to-end continuous plant of aliskiren hemifumarate built
by the Novartis-MIT Center for Continuous Manufacturing [13], [14]. In this
first of a kind demonstration, the authors highlighted two main advances as the
most important factors in achieving their goal: 1) novel continuous processes
and pieces of equipment [13]; 2) the integration of cascaded continuous pro-
cesses aided by process analytical tools and control loops [15]. This thesis fo-
cuses on the former, in the context of pharmaceutical crystallization.
1.2 Pharmaceutical Crystallization
Crystallization, the process in which crystalline solids are precipitated, typ-
ically from a supersaturated solution, is one of the most prominent downstream
processing steps in the manufacturing of active pharmaceutical ingredients (APIs)
[16]. Its importance is signified by the fact that more than 90% of APIs are for-
mulated as crystals [17]. Ideally, the output of crystallization is a population of
particles with a narrow size distribution, uniform shape and of the desired crys-
talline form [18], [19]. Such a particle population possesses the advantage of
’direct tablettability’ and requires little or no additional unit operations before
formulating the solid dosage [20]. However, achieving such an exquisite control
is rarely possible, as crystallization is an extremely complex phenomenon, and
our understanding of the underlying physics is still limited.
Conceptually, the process of crystallization is separated into two phases:
nucleation and growth [21]. In practice, this demarcation is used to indicate
the dominant mechanism of solid mass generation in a crystallization process
[18]. The first phase, nucleation, refers to the formation of ’nuclei’, i.e. clusters
of a new, thermodynamically more stable phase that are large enough to grow
spontaneously over time. According to the commonly used Classical Nucleation
Theory (CNT), the surface energy required to form a new phase competes with
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the free energy gain from phase transformation, resulting in a critical size above
which the further growth of the cluster results in a reduction of overall free
energy. Such clusters then tend to grow spontaneously [22], [23]. The rate of
formation of these clusters - the rate of nucleation - in a supersaturated solution







where J is the rate of nucleation in m−3s−1, A is a (temperature-dependent) pre-
exponential factor (also in m−3s−1), B is a kinetic barrier term that depends on
temperature and molecular properties and S is supersaturation, defined as a/aS
where a is the actual activity of the solute, and aS is the activity of the solute at
saturation [23], [24]. The calculation of these parameters will be discussed in
Chapter 3 in detail. Figure 1 shows how this steep dependence is exploited in
the most widely employed strategy to control particle size distribution in crys-
tallization: if the process starts out with a comparatively high supersaturation,
a large number of individual nuclei form, and subsequent crystal growth yields
a population of smaller particles as the solute is being depleted from the solu-
tion (i.e. nucleation is the dominant mechanism of solid mass generation [18]).
On the other hand, a lower initial supersaturation results in a smaller number
of nuclei that can grow into larger crystals. This simple principle to control
particle size distribution is at the heart of most highly optimized industrial crys-
tallization processes that typically involve the temporal variation of supersatu-
ration in the form of heating and cooling cycles or a separate ’nucleation’ and
’growth’ stage [25], [26]. However, the sheer number of variables still makes
crystallization more of an empirical endeavor than rigorous science, even if only
the aspect of nucleation is considered first. To start with, the validity of CNT
is limited [27], [28], as there are known cases of solutes exhibiting multiple
regimes of the J - S relationship and solutes that experience a radical drop in
nucleation rate at high supersaturations [18], [29]. Secondly, the presence of
3
Figure 1: Schematic of the most commonly employed strategy to control crystal
size distribution: if crystallization is performed at a high initial supersaturation,
a large amount of nuclei form, leading to a population of smaller crystals. On
the other hand, crystallization at lower initial supersaturation values produces
few nuclei which then grow into larger crystals [18].
a heterogeneous interface within a supersaturated solution greatly reduces the
free energy barrier for nucleation, thereby increasing nucleation rate [22]. This
implies that crystallization performed in a large vessel (be it a stirred batch tank
or a plug-flow reactor) is very likely to proceed via heterogeneous nucleation
on the vessel wall or impurities rather than homogeneous nucleation in solution
[30]. While the complete elimination of these unwanted impurities is usually not
feasible, adding ”impurities” or seeds to template crystallization is a well estab-
lished means of controlling size distribution and crystalline form [18]. Polymor-
phism, the ability of a single compound to exhibit multiple crystalline packing
arrangements, poses the final - and arguably the most formidable - challenge
in understanding and controlling nucleation. Different crystalline polymorphs
of the same molecule can have dramatically different downstream properties,
some of which directly affect the engineering and economic feasibility of a pro-
cess - such as their powder properties - while others influence the shelf life and
the in vivo performance of the drug - such as their stabilities and dissolution
rates [31]. Despite recent advances in the subject, most notably in templating
[32], [33] and nucleation in confined spaces [34]–[39], there is still no generally
applicable and robust method to predict and control polymorphism for a new
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compound [40], and even extensive screening exercises are known to miss more
stable or more desirable forms which can then incidentally appear and disrupt
an approved manufacturing process [41]. In addition, the appearance of multi-
ple polymorphs under the same nominal experimental conditions, concomitant
polymorphism [37], [42], is a very common phenomenon in API crystalliza-
tion, especially in molecules that have several polymorphs of nearly identical
stabilities (typically these are APIs that exhibit conformational polymorphism
[43]). To make matters even worse, some polymorphs tend to transform into
more stable ones in the solid state [44] or in the presence of solvent [45], the
prevention of which is of paramount importance in the final formulation of solid
dosage forms. Therefore, until these issues all get resolved, the development
of a crystallization process for a polymorphic compound still retains its artistic
aspect [31].
After nuclei form, crystal growth takes place. This step controls the final
morphology and habit of crystals. The morphology of a crystal is determined
by the facets present in the given crystal form, while crystal habit is determined
by the relative growth rates of these facets - i.e. the facets that grow slower are
the largest facets of a crystal [21]. The presence of disproportionately rapid-
growing facets can lead to needle-, blade- or plate-like crystals [21], [46]. Since
these habits tend to result in inferior downstream properties (such as longer
filtration times, poor packability, compactability and flowability), they are gen-
erally undesirable from a processing standpoint [18], [47]. Crystal habit (i.e. the
growth rate of facets) can be controlled by the rational design of intermolecular
interactions between crystal facets, growth units, the solvent and additives in an
academic setting [48]–[51]. In practice, however, the semi-empirical approach
of solvent screening is still the most widely used technique to regulate crystal
habit [18].
Despite all the efforts and techniques discussed above, many currently avail-
able API crystallization processes still yield acicular or blade-like particles.
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Therefore, the downstream process of transforming these crystals into a mar-
ketable form (such as tablets) often requires milling and comminution to pro-
duce uniform crystals of the desired size [52]–[54]. These steps are not only
energy intensive, but can result in complications, such as solid-state polymor-
phic transformation [55]. Next, the resulting crystals are typically blended with
excipients, another step that, beside being stochastic in nature [56], is not fully
understood in terms of API-excipient interactions [57]–[59]. Finally, the gran-
ulation of the API-excipient particles to a tablettable solid form is yet another
energy- and time consuming step that might result in excessive dust formation
in the case of dry granulation [60] or undesirable polymorphic transformations
during wet granulation [61]. To avoid at least some of these additional process-
ing steps, one would require a powder with superior flowability, packability,
and compactability. The next section introduces a technique that is capable of
producing such powders: emulsion-based crystallization.
1.2.1 Emulsion-based Crystallization
History, Categorization and Applications
Emulsion-based crystallization is the process in which crystallization occurs in
the presence of an emulsion (i.e. a dispersed liquid phase within an immiscible
continuous phase) that can be stable, metastable, or transient. The technique
arose in 1982, when Kawashima et al. applied their insights of spherical aggre-
gation of sands in presence of a bridging liquid [62] to API crystals, and defined
a solvent-antisolvent-bridging liquid system for salicylic acid to produce spher-
ical crystalline agglomerates (SAs) [63]. Although in their study crystalliza-
tion was performed before the bridging liquid was added to form the emulsion
and bring the individual crystals together, this piece of work inspired much of
the emulsion-based API crystallization methods that have been developed since
then. These techniques can be divided into four major categories: spherical ag-
glomeration (Kawashima’s method), (quasi-) emulsion solvent diffusion, evapo-
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rative emulsion crystallization, and melt crystallization from emulsions. Figure
2 describes the differences between these techniques.
Figure 2: Schematic explaining the differences between the four major cate-
gories of emulsion-based crystallization: a) spherical agglomeration, b) emul-
sion solvent diffusion or quasi-emulsion solvent diffusion, c) evaporative crys-
tallization, d) emulsion-based melt crystallization.
In spherical agglomeration, crystals are pre-formed by cooling, antisolvent
addition, or reactive crystallization, and a bridging liquid is added to form an
emulsion [63]–[65]. This bridging liquid is selected so that it preferentially
wets the formed crystals which then aggregate via two possible mechanisms,
depending on the size of the bridging liquid droplets, and therefore, agitation :
1) if the droplets are significantly larger than the crystals, crystals will partition
into the droplets, and spherical particles form (shown on Figure 2a); 2) in all
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other cases, aggregation happens via the coalescence of droplets on the surface
of the crystals, producing irregular agglomerates [64]. Owing to its relatively
well understood mechanism, spherical agglomeration remains the most popular
emulsion-based API crystallization technique. Solvent-bridging liquid systems
have been developed for an extensive variety of API molecules (e.g. naproxen
[66], ibuprofen [67], aspirin [68] - see Table 1 of reference [65] for more exam-
ples).
Emulsion solvent diffusion or quasi-emulsion solvent diffusion (ESD or
QESD), shown in Figure 2b, relies on a completely different mechanism of
agglomerate formation. In this technique, the API solution is dispersed in a
partially (ESD) or completely miscible phase (QESD) that contains the antisol-
vent [69]–[71]. While in the case of QESD these emulsions are transient - hence
the name - supersaturation is typically achieved rapidly by the inter-diffusion of
the solvent and the antisolvent between the two phases, and crystallization oc-
curs within or at the surface of the droplets. According to a series of extensive
experimental and modeling analyses performed by Espitalier et al., the final
agglomerate structure is determined by an interplay of heat and mass transfer
and the hydrodynamics in the system [72], [73]. Their study suggests that be-
side the ratio and the relative temperatures of the two phases [72] the presence
of internal circulation within the emulsion droplets above a critical radius (∼450
µm) is necessary for a homogeneous supersaturation profile and a homogeneous
agglomerate structure, whereas the opposite leads to core-shell structures [73].
Akin to spherical agglomeration, the ESD and QESD methods have success-
fully been applied to a wide variety of molecules [74]–[77]. Aside from the host
of QESD systems, a very innovative ESD study was carried out by Tanaka et
al., where aqueous solutions (of glycine or sodium chloride) were atomized and
sprayed directly into an antisolvent (1-butanol or 2-butanone), resulting in com-
pact SAs [78]. Finally, several studies of ESD and QESD show that the presence
of phase boundaries lends itself to the exploration of surface-active additives to
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control the outcome of the process. Firstly, because QESD relies on transient
emulsions, the short term stability of these emulsions is of great importance in
forming spherical particles - Teychene and Biscans even contend that it is im-
possible to perform QESD-type spherical crystallization without additives due
to secondary agglomeration (SAs sticking together) in their absence [79]. On
the other hand, these additives can also play additional roles, such as influencing
the habit or polymorphic form of crystals that constitute the SAs [80].
The third emulsion-based crystallization technique, evaporative crystalliza-
tion, is also the most relevant for this thesis (Figure 2c). Here, the API solution
is dispersed as droplets in an immiscible continuous phase. Subsequent evapo-
ration of the solvent through the continuous phase leads to crystallization within
the droplets. Interestingly, this conceptually straightforward method generated
only a few studies after surfacing in 1993 when Sjostrom et al. used it to crys-
tallize a hydrophobic drug from an oil-in-water emulsion [81], [82]. Later on,
the Davey group applied the technique to aqueous solutions of glycine. In their
2002 paper they demonstrated that the dimensions of the emulsion generated can
affect both spherical agglomeration and polymorphic outcome: in macroemul-
sions they produced SAs of the β polymorph, while in microemulsions and
lamellar phases single crystals of the stable γ polymorph could be obtained
[83]. Their 2009 study, which is one of the starting points of this thesis, inves-
tigates the role of operating conditions and surface-active additives in the batch
emulsion-based crystallization of three water-soluble molecules (ephedrine, glu-
tamic acid hydrochloride and glycine) [84]. They found that crystallization in
such batch systems typically takes several hours, and vigorous stirring is neces-
sary to obtain agglomerates of a reliable quality. In the case of glycine, some
surfactants, particularly CTAB could largely improve the structure of the SAs
obtained while controlling the polymorphic outcome (increasing the fraction of
β-glycine in a mixture of the α and β polymorphs) [84]. This example shows
that evaporative emulsion-based crystallization also lends great opportunities for
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the exploration of additives to control SA structure and polymorphic outcome.
Beside the studies mentioned above, our group explored functionalized silica
nanoparticles as a means of polymorphic control in the emulsion-based crystal-
lization of glycine. It was found that by appropriate selection of nanoparticle
surface properties (in this case, surface charge) the glycine-glycine and glycine-
surface interactions could be tuned to achieve polymorphic control [85].
Finally, melt crystallization from emulsions (Figure 2d) bears both histori-
cal, scientific and industrial relevance. In this technique, the dispersed phase of
the emulsion is a melt, and supersaturation is induced by cooling the emulsion
below the melting point. Historically, Vonnegut [86] was the first to point out
that by splitting a metallic melt into a large number of small droplets allows for
the decoupling of nucleation from growth (i.e. for one and only one nucleation
event to occur per droplet) and Turnbull and Cech [87] realized that the number
of droplets will be significantly greater than the number of impurities present
in the system, thereby confining heterogeneous nucleation to a small fraction of
the droplets. Thus, in such a system, one can study homogeneous nucleation.1
While the study of nucleation kinetics certainly is one of the well-established
applications of emulsion-based (melt) crystallization [89], the significance of
Turnbull and Cech’s finding with respect to emulsion-based crystallization is
even greater from a purification standpoint: if the presence of impurities facili-
tates the formation of an undesirable side product, the confinement of the impu-
rities to a few droplets will greatly increase the overall purity of the product. In
the context of organic molecules, this concept was first applied by Davey et al. in
1995, when they purified a mixture ofmeta- and para-chloronitrobenzene below
the eutectic by emulsion-based melt crystallization [90]. Naturally, this concept
of superior purification also applies to (Q)ESD and evaporative emulsion-based
crystallization. From an API-crystallization perspective, a superior quality of
1In this thesis, ”homogeneous nucleation” refers to nucleation in the absence of extraneous
impurities. However, it must be noted that nucleation almost always occurs at a surface of some
sort [88].
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the produced crystals reduces the number of downstream processing steps, lead-
ing to a more streamlined, less costly process. Outside this remarkable appli-
cation, melt crystallization from emulsions is the subject of great interest in the
food and cosmetics industry, where the solidification of emulsified fats can be a
crucial determinant of the product quality [91] and where solid fat particles can
be used for the delivery of active ingredients [92].
Advantages and Challenges
While the previous sections implied several advantages associated with emulsion-
based crystallization, they are worth reiterating. To start with, the interest in
emulsion-based API crystallization arose with the need for API crystals that
have consistently good downstream powder properties: packability, flowability,
and (direct) tablettability. Spherical agglomerates, formed from emulsions, are
well known to exhibit these properties [74], [93], in addition to the superior
bioavailability of the small individual crystals that make up the SAs [63], [94].
Secondly, the number of impurities in an emulsion is usually much smaller than
the number of droplets. Therefore, impurities are confined to a minute frac-
tion of the droplets, which results in a better overall product quality [90]. Next,
the presence of a liquid-liquid phase boundary lends itself to the exploration of
additives to control the outcome of the process [80], [83]–[85].
The main challenges associated with emulsion-based crystallization all arise
due to the fact that these processes are typically performed in stirred batch
tanks that are prone to inhomogeneities in operating conditions. These inho-
mogeneities influence the outcome in two ways: 1) polydisperse populations
of SAs that will necessarily have non-uniform downstream properties [95], 2)
there is no way to pinpoint the exact operating conditions under which individ-
ual SAs formed, which means that current knowledge regarding the mechanism
of SA formation is typically based on post factum analysis of the product. These
challenges call for platforms which enable both the production of monodisperse
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emulsions and the on-line monitoring of SA formation. Fortunately, such plat-
forms already exist, and are extensively used for the precise execution of unit
operations both in academia and industry. An overview of these platforms, mi-
crofluidic systems, is presented in the next section.
1.3 Microfluidics
The general term ’microfludics’ refers to the manipulation of minute amounts
of fluids (in the nL-aL range) within channels of small dimensions (<1 mm)
[96]. Microfluidic devices or microreactors are pieces of equipment that facili-
tate such manipulations. The extensive use of such devices for research purposes
took off with the development of rapid prototyping techniques, most notably
soft lithography [97]. Microfluidics offers a diverse toolbox of stationary and
continuous flow unit operations that provide chemical engineers with distinct
advantages over conventional synthetic and analytical processes. These advan-
tages are all associated with the ease of control over processing parameters that
is enabled by the small dimensions of microreactors. Firstly, due to the high
surface to volume ratio of such small channels, reactions that require rapid heat
transfer can be performed with ease - an early and extremely illustrative exam-
ple is the application of a continuous flow microreactor to PCR (polymerase
chain reaction), a reaction that requires several heating and cooling cycles [98].
Secondly, hydrodynamic flow in microfluidic channels is usually laminar, which
enables an exquisite control over diffusive mixing times, allowing for interest-
ing applications [99]. It can therefore be seen that microreactors are usually
superior to their large-scale counterparts when the operation performed is lim-
ited by mass or heat transfer, i.e. when the reaction rate is comparable to the
heat or mass transfer rate [100]. However, it must be noted that the character-
istics listed above are also a pre-requisite of the usefulness of microreactors in
any particular reactive application, and attributing ’magical’ properties to mi-
croreactors has resulted in comic relief at the expense of the authors in at least
one reported case [101], [102]. Several collateral advantages of microreactors
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over their batch counterparts arise from the fundamental physical advantages
listed above. These include their small footprints per kilogram product [103],
their smaller reagent consumption when used for the purposes of gathering in-
formation (high throughput screening) [104], [105], their ability to safely carry
out otherwise hazardous reactions [106]–[108], their reduced environmental im-
pact due to their superior heat transfer properties (leading to a lower energy
consumption [109]) and their improved selectivity [110], [111]. Finally, as
mentioned above, microreactor technology is suitable for continuous process-
ing [112], and the scale-up of microreactors by scaling out (parallelization) is
conceptually straightforward [113], and has been pursued to various degrees of
industrial success [114].
The following sections will discuss the aspects of microfludics that are rele-
vant to this thesis: droplet microfludics and its use for microparticle production,
with a special emphasis on microfluidic crystallization
1.3.1 Droplet Microfluidics
Droplet microfluidics is the sub-field of microfluidics, in which two or more
immiscible liquid phases are injected to meet at a microfluidic junction to form
droplets (dispersed phase) in a carrier liquid (continuous phase) [115]. Perform-
ing various unit operations in droplet microfluidics rather than single-phase mi-
crofluidics has several distinct advantages. When one performs a chemical unit
operation, the process often requires contact and mixing between different liquid
phase reagents. In microfluidic channels, co-dispensing two miscible reagents
usually leads to a laminar co-flow scenario, in which the mixing time is con-
trolled by the characteristic diffusion length (and thus, channel dimensions).
However, for fast reactions, diffusive mixing might be inadequate and lead to
unwanted effects (such as undesired side products). In droplet microfluidics, on
the other hand, mixing times can be drastically reduced due to the shear-induced
recirculatory motion within the droplets [116]–[119].
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The other important property of droplet microfluidics is its capability of
monodisperse emulsion generation. The formation of droplets in microscale
geometries is governed by the balance between interfacial, viscous, and iner-
tial forces, which are affected by the surface properties and the geometry of the
microchannel, the presence of surfactants and the properties of the immiscible
phases [120]–[123]. By choosing the right combination of the aforementioned
conditions, microfluidic devices are capable of generating monodisperse emul-
sions of various compositions and morphologies [124], [125]. Besides simple
single emulsions, monodisperse multiple emulsions (or compound droplets) of
various morphologies [126], [127] can be produced by tuning the interfacial
properties of the continuous and dispersed phases [128]–[130]. A study by Lee
et al. has taken the idea of microfluidic multiple emulsions a step further by
showing that the internal structure of double emulsions can be tuned by ad-
justing the shear rate to achieve non-equilibrium morphologies [131]. Finally
co-dispensing a gas phase with the liquid phases, functional composite foams
[132] and reversibly attached gas-liquid compound droplets [133] of a remark-
able uniformity can be formed.
Studies performed in microfluidic droplets cover an immense range of fun-
damental, synthetic and analytical areas. Therefore, only two relevant applica-
tions will be discussed in the following sections: the production of micropar-
ticles in droplet microfluidics and microfluidic crystallization; the interested
reader is referred to three great comprehensive reviews for other applications
[115], [116], [134].
Droplet Microfluidics for Microparticle Production
In the microfluidic production of microparticles (the size of which is typically
of the order of tens to hundreds of microns), monodisperse microfluidic emul-
sions are generated and used as templates for particle formation. Beside the fact
that the morphology of these particles is often inaccessible with conventional
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methods, the monodispersity of microfluidic particles generally makes them su-
perior for most applications [135], [136]. The most obvious candidates that can
be turned from monodisperse microfluidic droplets into particles are polymers:
typically, a monomer is first emulsified in an inert continuous phase, followed by
a curing step that preserves the morphology of the droplets, thereby producing
monodisperse polymeric microparticles [137]. Initially, however, particle mor-
phologies were restricted to spherical and deformed spherical shapes (i.e. disks,
rods, and cylinders) that could be obtained through the geometric confinement
of droplets in the microchannels [138], [139]. To circumvent these constraints
of droplet microfluidics, two inventive methods, continuous-flow lithography
[140] and stop-flow lithography [141] went back to single-phase flow to syn-
thesize polymeric particles of arbitrary shapes specified by a lithographic mask.
The high resolution of stop-flow lithography, in particular, made the technique
especially suitable for the synthesis of bar-coded microparticles that are advan-
tageous for multiplexed biological assays [142].
Beside homogeneous polymeric microparticles that are either functional per
se (e.g. for chromatographic use [137], [143]) or bear a functional payload (e.g.
polymerized ionic liquid microbeads loaded with pH-responsive dyes [144]),
there is a great interest in microstructured particles with well-defined domains.
These microstructured particles can both be synthesized in single and multi-
ple emulsions. In single emulsions, the microstructure is typically generated
through a phase separation or a self assembly process, such as the synthesis of
porous polymeric microbeads in presence of a porogen [145], the partitioning
of microgel suspensions [146], [147], or colloidal self assembly through a re-
active [148], [149] or evaporative pathway [150], [151]. Double emulsions, on
the other hand, are inherently inhomogeneous, and can directly be used as tem-
plates for microstructured particles [126]. When the outer layer of a double or
multiple emulsion is polymerized or solidified, microcapsules loaded with the
innermost phases form [126], [127], [152]. These capsules, in turn, can be engi-
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neered to respond to various stimuli, and are therefore very promising vehicles
for controlled delivery and release of active ingredients [152], [153]. Finally,
polymerizing one segment of a biphasic compound droplet can yield particle
morphologies that result from sphere-sphere intersections, such as lenses, hemi-
spheres, and dimpled spheres [154].
One class of microparticles produced in microfluidics, that of crystals, is of
special relevance to this thesis, and will therefore be discussed in detail in the
next section.
1.3.2 Crystallization in Microfluidics
The precise spatio-temporal control of operating conditions achievable in mi-
crofluidics, especially coupled with the compartmentalization of the reagents
in droplet microfluidics, makes these platforms very attractive for performing
crystallization experiments. Previous research on crystallization in microfluidic
systems took two major directions: data acquisition and the production of crys-
tals.
Microfluidic Crystallization for Data Acquisition
In the most widespread application of microfluidic crystallization, populations
of microfluidic droplets are treated as individual, nanoliter-sized batch crystal-
lizers with a precise control over operating conditions. These populations of
uniform droplets can then be used to gather statistically significant information
about various aspects of crystallization [155].
Firstly, as mentioned in the previously, segmenting a solution into small
droplets is an ideal way to probe nucleation without disturbances from extra-
neous impurities. In fact, Vonnegut and Turnbull’s aforementioned studies on
the subject [86], [87] inspired most nucleation-related research in microfluidics.
Since nucleation is inherently a stochastic process, and microfluidic droplets are
far from the thermodynamic limit [30], [156], a series of studies in the 1950s
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established that in a droplet-based system with sufficiently fast crystal growth
(so that only one nucleation event can happen within a droplet) and a constant
supersaturation, the probability of no nucleation observed within a droplet over
time, P0(t), is governed by the following equation [157], [158]:
P0(t) = exp(−JVt) (1.2)
where J is the nucleation rate,V is the volume of the droplet and t is time elapsed
after the attainment of supersaturation. In a statistically significant population
of droplets, this probability corresponds to the fraction of droplets that have not
yet crystallized at a given time point [158]. The populations of droplets used in
these studies, however, were far from monodisperse, making the extraction of
meaningful data difficult [159]. An 1959 study by White and Frost was the first
to overcome these challenges and extract nucleation rates from monodisperse
emulsions [160]. These emulsions were generated in an ”oil flow dropper”, a
device conceptually very similar to those used in modern capillary microflu-
idics [125], [126]. Since White and Frost’s pioneering paper, several microflu-
idic devices and methods have been invented to gather insights about the nucle-
ation kinetics of a large variety of materials: small inorganic [161] and organic
molecules [162]–[164], colloidal crystals [165], and proteins [166]–[168]. The
theoretical considerations of stochastic nucleation have also been refined by Goh
et al. to account for droplets with multiple nucleation events and time-varying
volume or supersaturation [169] (the specifics of which will be discussed and
utilized in Chapter 3). Recently, Chen et al. coupled this theoretical advance-
ment with experimental data and a numerical algorithm to identify upper and
lower bounds of nucleation rates [29]. This approach can be used to identify the
exact dependencies of nucleation rates at higher supersaturations [29].
High throughput screening of crystallization conditions is the other data ac-
quisition method that is greatly improved by droplet microfluidic techniques.
The crystallization of proteins, in particular, is a well-known challenge that tra-
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ditionally requires a lengthy screening process to obtain a diffraction-quality
single crystal [170]. The ability of microfluidic setups to rapidly screen a large
piece of operating parameter space with high precision generated several well-
executed studies to explore conditions that yield diffraction-quality protein crys-
tals [171]–[174]. Since crystallization processes are often governed by kinet-
ics, an especially interesting extension of screening studies is the exploration
of kinetic pathways, i.e. trajectories on the phase diagram taken during crystal-
lization to obtain protein crystals of superior quality [175]–[177]. In addition
to optimizing protein crystallization conditions, kinetic pathway screening can
lead to insights about the formation of different polymorphs in small molecule
crystallization, which can then aid the rational design of API crystallization pro-
cesses [178]–[180].
Production of Crystals in Microfluidics
One could reason that the precise metering of reagents and the exquisite con-
trol of operating conditions in microfluidics might enable continuous, scalable
production of crystalline materials with tailor-made kinetic pathways to obtain
the desired crystal form. However, there is a major limitation of performing
crystallization in microreactors: the formation of crystalline solids in such con-
fined spaces quickly leads to flow disruption and channel blockage [155]. While
solids deposition can be prevented during the synthesis of nanomaterials by con-
fining the reaction to droplets [181], the deposition of micron-sized crystals is
almost inevitable. Therefore, it is not surprising that the first report on a robust
on-chip crystallization process of pharmaceutically relevant microparticles was
only published in 2012, when Sultana and Jensen reported a continuous, seeded
microfluidic crystallization platform for API molecules [182]. However, the fact
that extensive reactor design, seeds, and surface modifications of the microchan-
nel had to be used in order to overcome the challenges of precipitating crystals in
a microchannel highlight the difficulties of such an endeavor [182], [183]. Be-
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side this study, pharmaceutically relevant on-chip microfluidic crystallization is
confined to nanomaterials produced either in flow [184] or in microfluidic spray
driers [185], [186] and the thermal quenching of fats to produce microparticles
of various morphologies [187].
A promising alternative to on-chip crystal production is performing the crys-
tallization step off-chip while retaining monodisperse microfluidic droplets as
templates. Prior to the studies presented in this thesis, this technique has only
been explored in the context of fats [188], [189] and colloidal crystals [151],
[190]. The work presented herein fills this gap, and extends this method to API
crystallization.
1.4 Thesis Outline and Contributions
This thesis presents the development of a continuous, scalable, microfluidics-
enabled emulsion-based crystallization platform for the production of uniform
spherical agglomerates of API crystals. Firstly, it is shown in Chapter 2 that
monodisperse microfluidic droplet generation in conjunction with off-chip thin
film evaporation can produce SAs of a model API compound, glycine with an
unprecedented uniformity and drastically reduced crystallization times. In ad-
dition to solving problems faced by batch emulsion-based crystallization, de-
coupling emulsion generation from crystallization also circumvents the typical
microfluidic crystallization challenge of clogging. In addition, microscopic ob-
servation of the crystallizing droplets revealed the distinct phases of the process
that have previously not been reported due to the lack of on-line monitoring
opportunities in conventional systems.
Next, in Chapter 3, the effect of operating conditions (temperature, droplet
size, rate of srhinkage) on the morphological outcome of thin-film spherical
crystallization is investigated and modeled. It is determined that spherulitic
crystal growth [191]–[193] is required to obtain complete SAs, which can only
be achieved if a critical supersaturation is attained within a droplet before nucle-
ation occurs. This scenario is modeled by using the classical nucleation theory
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[22], [23] in conjunction with a theory developed for nucleation in small vol-
umes with time-varying supersaturation [169] to obtain P0(ts), the probability
of no nucleation occurring within a single droplet before attaining critical su-
persaturation. This calculated probability is compared to fI , the experimentally
observed fraction of complete SAs among the ensemble. The experimentally
observed trends are accurately captured by the simulations.
To move on from the semi-batch platform used in Chapters 2 and 3, Chap-
ter 4 presents a proof-of-concept continuous emulsion-based crystallizer based
on the belt evaporator. This prototype crystallizer is capable of producing high
quality SAs at the rate of ∼1-10 g/day, while having a volumetric footprint of
only ∼10 L. Owing to the straightforward scale-up of this process by scaling out,
its throughput makes the setup suitable for the production of small- to medium-
volume, high value APIs.
Finally, Chapter 5 explores future prospects of the developed process. First,
ongoing research on advanced microfluidic formulation methods for a selected
hydrophobic compound (ROY) with an excipient is presented. It is shown that
by tuning the rate of evaporation, the morphology of the agglomerates and the
polymorphic form of the crystals can be tuned. It can be anticipated that such
advanced processes, along with scaled-up continuous microfluidic crystallizers
will be the main directions of research and industrial development in the near
future. The second part of this chapter focuses on potential issues that have to
be overcome in order to bring the process up to speed with potential industrial
applications. In the final part of Chapter 5, potential fundamental research di-
rections are addressed. These directions have been opened up by the platform
developed in Chapter 2, which enables the investigation of spherical crystalliza-
tion dynamics in unprecedented detail.
In summary, the main contribution of the work presented herein is the start-
to-finish development of a scalable, continuous, microfluidics-enabled crystal-
lization process for the production of uniform and spherical particles of API
20
crystals. Scientific contributions include the elucidation of the nucleation kinet-
ics and formation mechanism of SAs, the delineation of the operating parameter
space under which SAs form and the mathematical modeling thereof. Owing to
the increased need for novel processes and equipment for continuous pharma-
ceutical manufacturing, this work is of direct industrial relevance.
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2 Spherical Crystallization of Glycine FromMonodis-
perse Microfluidic Emulsions
2.1 Introduction
As seen in Chapter 1, emulsion-based crystallization to produce spherical
crystalline agglomerates (SAs) is an attractive route to control crystal size and
shape during the downstream processing of active pharmaceutical ingredients
(APIs). It was also discussed that conventional methods of emulsification in
stirred vessels pose several problems that limit the utility of emulsion-based
crystallization, such as the polydispersity of the resulting particles and the lack
of on-line monitoring opportunities.
In this chapter, a capillary microfluidic platformwas used to generate monodis-
perse water-in-oil emulsions, which, in conjunction with evaporative crystalliza-
tion on a flat heated surface, enables controllable production of uniformly-sized
SAs of glycine in the 35-150 µm size range. By performing the crystallization
step off-chip, the processing challenges previously associated with microfluidic
API crystallization platforms (such as clogging, and device fouling) were com-
pletely bypassed. Detailed characterization of particle size, size distribution,
structure and polymorphic form is reported. Furthermore, online high-speed
stereomicroscopic observations revealed several clearly demarcated stages in
the dynamics of glycine crystallization from emulsion droplets. Rapid droplet
shrinkage was followed by crystal nucleation within individual droplets. Once
a nucleus formed within a droplet, crystal growth was very rapid (complete in
0.1 s) and occurred linearly along radially advancing fronts at speeds of up to 1
mm/s, which suggests a spherulitic crystal growth mechanism. The spherulitic
aggregate thus formed ages to yield the final SA morphology. This aging mech-
anism was determined to be solvent-mediated phase transformation. Overall




Glycine (>99%), dodecane (>99%), Span-20, Span-80, and Trichloro-
(1H,1H,2H,2H-perfluorooctyl)-silane (97%) were purchased from Sigma-Aldrich
and used as received. Ultrapure water (18.3 M) obtained using a Millipore
MilliQ purification system was used to prepare aqueous glycine solutions. Ster-
ile syringes (3 and 10 cc) and sterile single use needles (21 G 1.5”) were pur-
chased from Terumo Corporation, Japan. Syringe filters (0.45 µm) were pur-
chased from Cole-Parmer. Microscope slides (Corning 75x50 mm) were used
as a crystallization platform and for sample collection.
A schematic of the experimental setup and procedure is provided in Figure
3. Monodisperse emulsions were produced in a coaxial capillary setup, in which
a round capillary (1 mm outer diameter) with a tapered end functions as a col-
lection tube and the two immiscible liquids are infused through a coaxial outer
square capillary (1 mm inner side). Two devices were used with different end
diameters of the tapered round capillary - ’narrow’: 90µm and ’wide’: 450 µm
- to generate droplets within two broadly different size ranges. Dodecane was
used as a continuous phase (CP) with a 2% (w/w) surfactant mixture consisting
of 70% Span-20 and 30% Span-80 (w/w) [84]. The dispersed phase (DP) was
a glycine solution saturated at room temperature (22 ◦C); therefore the glycine
content was approximately 24.4 g glycine/100 g water. This solution was fil-
tered through a 0.45 µm syringe filter before each experiment. As shown in
Figure 3, the glycine solution and dodecane-surfactant mixture were loaded into
separate syringes and infused into the capillary emulsion generator using sy-
ringe pumps (Harvard PHD 22/2000 series) at various flow rates. The emulsions
generated were directly dispensed for 10 seconds onto glass slides placed on a
hotplate (Thermo Scientific CIMAREC) set to 90 ◦C. The surface temperature
of the glass slides was measured with a thermometer (Lutron TM-914C) to be
84 ◦C. Imaging of the droplet breakup and crystallization was performed with
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high-speed digital cameras (Basler pI640 or Miro Phantom EX2) mounted onto
a stereomicroscope (Leica MZ16). An Olympus LG-PS2 light source with a
gooseneck was used for illumination.
Figure 3: Schematic of experimental setup. Emulsion generation is performed
in a concentric microfluidic glass capillary setup, where a square capillary (ID=1
mm) houses a tapered round capillary (OD=1 mm). The two ends of the square
capillary function as inlets and the round capillary functions as a collection tube
and outlet. The continuous phase (CP) of dodecane (with dissolved surfactants)
and a dispersed phase (DP) of aqueous glycine are infused by syringe pumps
into the square capillary. The emulsions are collected on a heated glass slide,
where evaporative crystallization occurs. A more detailed description of the
fabrication and assembly of the devices used is provided in Appendix A.
The SAs obtained were characterized in three different ways: microscopic
image analysis for size distribution studies, field emission scanning electron
microscopy (FE-SEM) for structural characterization and powder X-ray diffrac-
tion (XRD) for polymorphic characterization. For the size distribution studies
we used an inverted microscope (Nikon Eclipse Ti) operated in dark field mode.
The inbuilt software (NIS Elements 3.22.0) was used to measure the diameter
of the agglomerates (circle by three points method) and to estimate the aver-
age diameters and standard deviations based on measurements of at least 100
SAs. A field-emission scanning electron microscope (JEOL JSM-6700F) at 5
kV accelerating voltage was used to acquire further structural information on
the SAs. All samples were prepared on conventional SEM stubs with carbon
tape, and were coated with ∼10 nm of platinum by sputter coating. An XRD
diffractometer (LabX XRD-6000, Shimadzu) with characteristic Cu radiation
was used for polymorphic characterization. The crystal samples were ground
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into a fine powder and filled into the cavity of an aluminum sample holder that
was mounted to a motorized stage for sample scanning. The X-ray diffractome-
ter was operated at 40kV, 30 mA and at a scanning rate of 2◦/min over the range
of 2θ = 10−40◦, using the Cu radiation wavelength of 1.54 A˚.
2.3 Results and Discussion
2.3.1 Emulsion Generation
Two different end taper sizes were used for the circular capillary in the emul-
sion generator - see Figure 3 - to produce broadly two size ranges of aqueous
emulsion droplets that were classified as ’large’ (d0 = 200−320 µm range) and
’small’ (d0 = 70−120 µm range). By choosing appropriate combinations of oil
and water volumetric flow rates (as indicated in Table 1), droplets with tightly
controlled sizes and distributions could be dispensed in the above ranges. Typ-
ical standard deviations for the emulsion droplets were <1% in all cases, high-
lighting the efficacy of the capillary microfluidic method in generating highly
monodisperse water-in-oil emulsions.
Table 1: Summary of the experimental conditions and the properties of droplets
and agglomerates obtained. Condition: as seen on Figures 4 and 5; QCP : flow
rate of continuous phase; QDP : flow rate of dispersed phase; d0 : droplet di-
ameter (with a standard deviation of less than 1% in all cases); dA : average
agglomerate diameter; σdA : standard deviation of agglomerate diameters.
Condition Device QCP QDP d0 dA σdA
µL/min µL/min µm µm %
a Narrow 100 20 80 38 9
b Narrow 100 30 115 48 3
c Wide 1000 20 210 86 7
d Wide 1000 40 310 149 6
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2.3.2 Crystallization and Agglomerate Characterization
The emulsions generated were dispensed onto a heated glass slide maintained
at 84 ◦C via a short length of tubing, where they formed a thin film of ∼0.2-0.5
mm depth. The following sequence of phenomena were observed to occur in
each dispensed droplet: (1) rapid (i.e. within ∼10 s) shrinkage by ∼50% of the
dispensed diameter in all cases, (2) onset of nucleation, with nucleation times
varying from ∼10-300 s, (3) very rapid (<0.1 s) growth of the nucleus along
radially advancing fronts that eventually stopped at the droplet boundary and
(4) ageing of the crystal-filled droplet to yield spherical agglomerates (SAs).
These individual stages are discussed in further detail in the next sections.
Figure 4: (a)-(d) Dark-field microscopy images of spherical agglomerates ob-
tained under different conditions, (e) SA size distribution histograms for these
samples (key parameters are summarized in Table 1) and (f) comparison of the
dispensed droplet diameters with the average SA sizes obtained; droplets shrink
to ∼50% of their original size before crystallization initiates.
A collection of microscopic images (under dark-field illumination) of SAs
obtained under different conditions, histograms of particle sizes from the four
samples, and a comparison of droplet and SA sizes are provided in Figure 4.
The smooth size distribution of SAs obtained by this method is much narrower
than that of comparable SAs produced by batch crystallization [84], the most
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striking difference being the complete absence of extremely small or large SAs.
For all sizes shown here, the diameter of SAs obtained is ∼50% of the original
droplet diameter. Similar observations regarding droplet and SA diameters were
reported by Chadwick et al. for the batch case [84]. Sphericity of the agglom-
erates was confirmed by field-emission scanning electron microscopy (FESEM)
observations with a tilted stage (Figure 5). It was observed that the size of the
individual crystals that constitute the SAs increases as the size of the SAs in-
creases. Larger SAs (>100 µm) were also more susceptible to breakage and
flattening during handling and characterization, suggesting a balance between
the structural integrity and the size of the SAs obtained, which has to be con-
trolled by optimizing crystallization parameters (such as droplet size and the
rate of supersaturation-generation).
Figure 5: FE-SEM images of SAs obtained under different conditions (Table 1
and Figure 4). Smaller SAs [(a) and (b)] are comprised of compactly packed
crystals of small (<10 µm) size while larger SAs [(c) and (d)] consist of larger
and, for the latter case, loosely packed crystals.
Finally, XRD results confirmed that the SAs obtained were composed of
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predominantly the α polymorphic form under all conditions (a sample XRD
pattern is provided in Figure 6; α−glycine has characteristic peaks at 2θ values
of 15, 19, 24 and 29.8◦ [194]), the β and γ forms were present only in minute
amounts. It should be noted that this is the expected result when crystallizing
glycine from an aqueous solution [83].
Figure 6: XRD characterization of SAs obtained from condition (d) (Table 1).
Characteristic peak positions of all three polymorphs are indicated; the α poly-
morphic form is the dominant component.
2.3.3 Crystallization Dynamics
Stereomicroscopic observations have shed light on the various stages of crys-
tallization. The dispensed emulsions started crystallizing on the heated slide
after a short induction time (∼10-40 s) in all cases, with a typical ensemble
crystallization time of a few minutes. This overall crystallization time is signifi-
cantly less than that observed in batch processes (typically on the order of hours
[84]). As mentioned briefly in the previous section, the droplets first shrank
rapidly as water evaporated through thin films of oil surrounding the droplets on
the slide, following which nucleation occurred within the individual droplets.
Time-resolved droplet shrinkage and nucleation statistics measurements were
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conducted (sample results provided in Figure 7) to uncover the details of crys-
tallization dynamics.
Figure 7: (a) Plot of droplet size versus time indicating shrinkage dynamics,
with an overlayed histogram of nucleation statistics (number of droplets with
nuclei in a given time interval) for a population of droplets of ∼140 µm initial
size. Droplets shrink rapidly in <10 s, followed by nucleation events in individ-
ual drops. (b) Statistical analysis of nucleation induction time measurements for
the same sample: the horizontal axis shows the time after dispensing (t), while
the vertical axis corresponds to the natural logarithm of the probability (P0 ) of
no nucleation in a drop within a time t (as obtained from five different ensem-
bles of drops, with a total of 415 nucleation events observed). A compressed
exponential model P0 = exp[−t/τ]β was fitted to the data with an R2 value of
0.99, an average induction time τ of 102 s, and a compressed exponent β of
2.02.
Firstly, it can be seen that droplets underwent rapid initial shrinkage fol-
lowing which the size remained essentially constant; the onset of nucleation
and crystallization occurred during this latter phase. Shrinkage was complete
within ∼5 s while the earliest nucleation event occurred at ∼25 s, implying that
nucleation events could essentially be decoupled from shrinkage. Next, on-
line nucleation induction time measurements were conducted on ensembles of
droplets via direct microscopic observation, with ensemble sizes varying from
50-200; a typical histogram of measured nucleation events is superimposed in
Figure 7(a). Figure 7(b) shows a plot of the logarithm of probability of observ-
ing no nucleation event in a given drop versus time t , and reveals an interesting
feature of nucleation in this system. If nucleation in this system were a simple
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homogeneous Poisson process
P0 = e−t/τ (2.1)
with a constant rate parameter λ = 1/τ , the plot in Figure 7(b) would be linear.
However, clear deviation from linearity was observed and, remarkably, it was




with time constant τ ∼102 s and compressed exponent β ∼2, fits the data most
satisfactorily. The compressed exponential model reflects a non-homogeneous
Poisson process with a time-dependent rate parameter λ (t) ∼ t/τ2, which in-
creases with time [195].
These results are interpreted by commenting on the possible mechanisms
of nucleation within drops. Heterogeneous nucleation by external impurities
such as dust particles can be ruled out, because the likely number of impuri-
ties is significantly smaller than the number of droplets in an emulsion-based
system [90]. Moreover, it was observed that in the rare cases where a visible
impurity was present in a droplet - a fibrous dust particle for example - large,
faceted α-glycine crystals were obtained. If each drop is assumed to be isolated
from the influence of other drops in the ensemble, then two mechanistic candi-
dates remain for our consideration (i) homogeneous nucleation within the drops
and (ii) heterogeneous nucleation at the oil-water interface (aided by surfactants
or otherwise), which has been documented in several reports of crystallization
in emulsions [83], [84], [196]. While neither mechanism can be ruled out, it
should be noted that both can be modeled by homogeneous Poisson processes,
albeit with different time constants. However, attempts to fit the data with sim-
ple two-exponential models [197] were unsuccessful. On the other hand, the
compressed exponential process could accurately describe the process, as stated
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above. This model highlights an important fact about this experimental sys-
tem that the drops on the heated slide are not necessarily isolated from the
influence of events in surrounding drops. The increasing rate parameter of the
compressed exponential model likewise suggests that the presence of formed
SAs increases the likelihood of nucleation in the un-crystallized droplets. As
an extreme example of this phenomenon, it was observed that formed SAs can
trigger nucleation within droplets in their immediate vicinity (a sample image
sequence is provided in Appendix A).
Next, high-speed stereomicroscopic visualization at the single-droplet scale
provided insights into the physics of crystal growth. Nucleation typically oc-
curred at a random location within or at the surface of a droplet, and crystal
growth occurred rapidly from the nucleus along radially advancing fronts at
speeds of ∼1 mm/s. Digital image analysis of crystal growth within the droplets
was conducted by measuring the radial interface position from the nucleation
site r for several directions versus time t . The image analysis package of MAT-
LAB was used to measure the radius of the forming SAs: the images were
converted into binary images with a threshold value suitable for the individual
agglomerate. The number of black pixels was counted from the origin (set as the
nucleation site) in +X, -X, +Y, and -Y directions for each frame. The image was
rotated by 10 degrees and the process was repeated until the rotation reached
80 degrees. Digital micrographs captured at high imaging speeds and image
analysis results are provided in Figure 8 for selected typical cases. Interestingly,
linear crystal growth was observed (i.e., r∼ t) in all cases, strongly suggesting a
spherulitic growth mechanism observed commonly in impure melts, where crys-
tal growth is faster than diffusive mass transfer [191]–[193]. Simple estimates
of glycine concentrations within the droplets support the hypothesis that condi-
tions within the emulsion droplets after shrinkage are conducive to a spherulitic
growth mechanism. Assuming a uniform temperature of 84 ◦C, droplet shrink-
age of ∼50% and no glycine leaving the droplets, it can be estimated that su-
31
persaturation values within the shrunk droplets range between 3.5-6.5 (for the
range of drop sizes used in this study), with dissolved glycine concentrations of
18.6-20.0 kmol/m3 and water concentrations of 0.3 kmol/m3. These values cor-
respond to glycine concentrations of 1.3-1.5 g/mL, which are very close to the
solid density of glycine (∼1.6 g/mL). Moreover, drastic decreases in mutual dif-
fusivities have been reported for supersaturated aqueous glycine solutions, with
very low (<<10-9 m2/s) values above supersaturations of ∼1.5 [198]. Given
these facts, it is plausible that the contents within the droplets resemble impure
melts, with water acting as the impurity, in which the spherulitic crystal growth
mechanism has been well documented [191]. Further, extremely low molecular
diffusivities at high supersaturation could also account for the observation of
rapid initial shrinkage of droplets followed by a prolonged stagnation of their
sizes.
Finally, once formed, most agglomerates go through an aging process which
is typically completed within ∼3-10 s of crystallization, and leads to a coarser
surface, likely due to phase transformation and Ostwald ripening mediated by
trapped water within the agglomerate [45]. A typical series of microscope im-
ages showing the observable coarsening of an agglomerate is provided in Ap-
pendix A. In the next section, experimental evidence is provided to show that the
primary mechanism behind the aging process is solvent-mediated phase trans-
formation.
2.4 Aging and Polymorphism
As reported in Figure 6, the final SAs obtained from microfluidic emulsions
exclusively consist of α-glycine [199]. However, batch emulsion-based crystal-
lization experiments reported in the literature yielded a significant percentage of
β-glycine [83]–[85], with the only apparent differences of droplet size and the
overall crystallization time. It was also observed that not only do most agglom-
erates undergo an ’aging’ process of visually discernible coarsening (as opposed
to the relatively smooth structure of batch SAs), but larger SAs also consist of
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Figure 8: Growth of spherical agglomerates after the nucleation event: (a) high-
speed microscopic images of a growing SA obtained at the flow rate combina-
tion QCP =1000 µL/min, QDP =20 µL/min. (b) the evolution of a 110 µm SA
after the nucleation event. It can be seen that radial crystal growth, measured
as the position of the interface versus time, assumes a distinctly linear profile
(with crystallization speeds of ∼1.3 mm/s), a characteristic of spherulitic crys-
tallization. The inset shows an example of how crystal growth is measured via
digital image analysis: the radial interface position is tracked along a variety of
directions from the point of nucleation; a sample direction is indicated.
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larger individual crystals. The ’aging’ process can most likely be attributed to a
combination of solvent-mediated phase transformation [45] and Ostwald ripen-
ing [200] facilitated by the trapped water in the SAs’ structure. However, it is
very likely that one of these two processes is dominant, and experimental ev-
idence is provided below that ’aging’ is primarily caused by solvent-mediated
polymorphic transformation in the case of glycine SAs.
To test this hypothesis, Raman microscopy was used on the single SA scale
to determine the composition of smooth and coarse agglomerates. Crystallizing
droplet populations were dispensed on aluminum foil-coated glass slides, and
a Raman Workstation (Kaiser Optical) was used to acquire Raman spectra on
the microscopic level. Figure 9a shows a microscopic image of a representative
∼60 µm SA population crystallizing at room temperature (22 ◦C) along with the
Raman spectra of α-glycine, β-glycine and two typical ’smooth’ and ’coarse’
SAs in the 1300-1500 cm-1 range. This range was chosen because the other
ranges with representative glycine peaks suffered from significant interference
from the other compounds present in the emulsion. Specifically, the 1321 (β)
to 1324 cm-1 (α) shift of the CH2 wagging peak and the features around 1450
cm-1 were found to be the only reliable indicators of polymorphism[36], [201],
[202]. Smooth SAs were found to be predominantly made up of β-glycine,
while coarse SAs showed the predominance of the α polymorph, thus corrobo-
rating the dominant role of solvent-mediated phase transformation.
Further experimental evidence to support this hypothesis was gathered when
spherical crystallization experiments were performed in systems that preclude
or reduce the rate of polymorphic transformation. Figure 9b and 9c show SEM
micrographs of SAs obtained from two such experiments. Figure 9b shows SAs
that consist of α and γ-glycine, induced by the addition of sodium dodecyl sul-
phate to the aqueous phase under conditions that were presented in another paper
by our group [203] (and that are nearly identical to the ones presented in Chapter
2), while Figure 9c shows SAs of L-alanine, another simple amino acid obtained
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Figure 9: a) a population of crystallizing 60 µm agglomerates under a Ra-
man microscope at 22 ◦C along with the Raman spectra (in the 1300-1500
cm-1 range) of pure glycine polymorphs and two representative SAs in differ-
ent stages of ’aging’. The 1324 cm-1 peak of the α-polymorph is highlighted
with a dashed line for clarity. It can be seen that the recently crystallized and
still smooth SAs predominantly consist of β-glycine, and ’aged’ SAs are pre-
dominantly made of α-glycine. This observation suggests that SA ’aging’ is
a solvent-mediated phase transformation process in the case of glycine. b-c)
Spherical agglomerates of b) α and γ-glycine, and c) L-alanine, two systems in
which solvent-mediated polymorphic transformation is very slow or nonexistent
(respectively). The surface of these agglomerates is extremely smooth, with no
observable faceted features.
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under identical to the ones described in Chapter 2. L-alanine has only been re-
ported to exhibit polymorphism under high pressure [204] or laser irradiation
[205], and therefore could be expected not to undergo a phase transition from a
simple evaporative experiment. Owing to the similar experimental conditions,
it could also be expected that if Ostwald-ripening played a significant role in the
aging phenomenon, these SAs should consist of rather large individual crystals.
As can be seen, however, this is not the case: these agglomerates consist of very
small domains; note that even crystalline facets are difficult to identify, whereas
even the smallest glycine SAs in Figure 5 that have the smoothest texture, are
clearly faceted.
In the case of α- and γ-glycine SAs, one could still expect that the transfor-
mation of α-glycine to the more stable γ-glycine could lead to the appearance
of faceted γ-glycine crystals in the SAs’ structure. However, no such crystals
were observed, most likely due to the fact that this transformation is very slow
[201] because of the relatively small difference between the stability of the two
enantiotropic polymorphs [206]. Moreover, the formation of β-glycine in the
first place is not unexpected, as it was observed to crystallize from highly su-
persaturated aqueous glycine solutions in a study by Ferrari et al. [207]. They
also pointed out that β-glycine rapidly transforms to α-glycine in pure aque-
ous solutions, and that this transformation is governed by the dissolution rate of
β-glycine crystals [207]. Therefore, it seems that for ’aging’ to occur, the pres-
ence of a metastable form with respect to another is not enough: the difference
between the stabilities (and the dissolution rates) has to be high enough. Alter-
natively, if one could find a solute that has a very high dissolution rate, Ostwald
ripening might emerge as the dominant coarsening process. Finally, it should be
noted that the structure of un-aged SAs is very fragile, as indicated by the fact
that they regularly deform during SEM sample collection (Figure 9b-c). Hence,
a certain degree of ’aging’ might, in fact, be required to obtain SAs of reliable
quality. These insights provide valuable guidelines for future efforts to produce
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SAs of controlled quality, especially for compounds that exhibit polymorphism.
2.5 Concluding Remarks
In summary, spherical crystallization of glycine was demonstrated in monodis-
perse emulsions generated using a simple capillary-based microfluidic device
and a heated thin-film evaporation platform. Spherical glycine crystal agglom-
erates were produced with a remarkable level of control over shape, size and
size-distribution in an industrially relevant size range. By decoupling emulsion
generation from crystallization, the well-known disadvantages of microfluidic
crystallization platforms, such as clogging and fouling, have been completely
bypassed. This study has also shed light on various operative phenomena during
emulsion-based crystallization. It was shown that the formation of SAs occurs
through the following four steps: (1) shrinkage of the droplets to a limiting size,
(2) stochastic nucleation within the droplets that follows a compressed exponen-
tial model, (3) spherulitic crystal growth within the shrunken droplets, (4) aging
of the spherulitic aggregate through solvent-mediated phase transformation.
This study also raised several interesting fundamental and practical ques-
tions and challenges while establishing the technological base for the remaining
chapters of this thesis. Keeping in mind that the main goal of this thesis is to
build a general, continuous, and scalable crystallization platform, there are three
main issues that have to be resolved. Firstly, from a processing standpoint, the
understanding of these previously unreported crystallization phenomena within
emulsion droplets is crucial in identifying the conditions under which spherical
agglomerates of a desired quality can be produced. In pursuit of this understand-
ing, the processing parameter space is explored and the process is modeled in
Chapter 3. Next, the scalability of emulsion generation, especially in the context
of low-volume high-value pharmaceuticals, can be achieved by parallelization
of the microfluidic emulsion generators. However, the platform presented in this
chapter couples continuous droplet generation with batch evaporation. There-
fore, it is semi-batch in nature. In order to achieve a fully continuous crystal-
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lization process, a continuous downstream unit is required. This unit, a novel
continuous thin-film evaporator, is presented in Chapter 4. Finally, the appli-
cability of the method is explored in the context of advanced formulations in
Chapter 5.
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3 Dynamics andMorphological Outcomes in Thin-
film Spherical Crystallization
3.1 Introduction
As reported in the previous chapter, agglomerates undergo spherulitic crystal
growth after nucleation. This mechanism is particularly interesting because of
its generality: besides its ubiquity in crystallization from metallic and polymeric
melts [191], it has also been observed during the precipitation of small organic
and inorganic molecules in reactive [208], evaporative [84] and antisolvent crys-
tallization [79], [164]. Spherulitic crystallization typically occurs under highly
non-equilibrium (i.e. supersaturated) conditions when crystal growth is faster
than the reorientation of molecules at the growth front, which can result in poly-
crystalline aggregates of a variety of morphologies with a spherical shape at
larger length scales [193]. The fine details of the actual spherulitic growth pat-
tern and the final morphology of these aggregates is highly dependent on the
operating parameters (such as supersaturation and temperature); it is generally
accepted that a higher supersaturation leads to more compact spherulites due to
the larger degree of branching [193]. These differences in the final morphology
of the agglomerates will affect the downstream processing properties of the re-
sulting powder. For example, loosely packed or fragile spherulitic aggregates
have been reported to shed their individual crystallites and cause filtration prob-
lems in at least one case [209]. A number of studies have focused on these ef-
fects in conventional batch crystallization systems, reaching conclusions that are
in line with the theoretical framework of spherulitic growth [208], [210], [211].
As mentioned above, however, the inherent spatio-temporal inhomogeneity of
operating conditions in a batch crystallizer and the inherent difficulty in relating
these to measurements of particle properties, typically made post factum, sets
limits to the experimental understanding of spherical crystallization.
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In Chapter 2 it was shown that thin-film evaporative crystallization from
microfluidic emulsions not only facilitates the production of uniform spherical
agglomerates (SAs), but also enables the on-line observation of the process. It
can be anticipated, however, that by changing processing parameters, such as
droplet size, film thickness and substrate temperature, the formation process,
and hence the morphology of the obtained SAs could be influenced. Moreover,
from a processing standpoint, it would be crucial to identify regions of the multi-
dimensional processing parameter space that yield SAs of a desired morphology.
This study exploits the advantages of monodisperse microfluidic droplet popula-
tions and the ability to monitor the crystallization process in individual droplets
to gain further understanding of glycine SA formation in this system. Specifi-
cally, the influence of droplet size, shrinkage rate and temperature on the crys-
tallization process was investigated. Experimental results indicate that lower
temperatures, smaller droplet sizes, and faster shrinkage generally favor the for-
mation of complete, spherical, compactly packed SAs (termed ’Morphology I’,
the generally desired morphology), while the converse leads to the formation of
incomplete SAs or single crystals (’Morphology II’ see Figure 13 for a visual
description of the process). Further, it was shown that these measured param-
eters influence the progression of two important inferred parameters over time
- supersaturation and the rate of nucleation. It was hypothesized that undesired
morphologies are obtained when nucleation events occur in the droplets before
they have reached the high supersaturation required for spherulitic growth. A
mathematical model was formulated to test this hypothesis; using the classical
theory of nucleation [22], [23] and by modeling nucleation within microfluidic
droplets with time-varying supersaturation as a non-stationary Poisson process
[169], a self-contained model was obtained. This model captures the competi-
tion between supersaturation and nucleation throughout the process. The results




Monodisperse microfluidic emulsions were generated with the same mate-
rials and methods as in Chapter 2. Flat bottom glass Petri dishes (ID = 26mm)
made of borosilicate were manufactured by HCS Scientific & Chemical Pte Ltd,
then silanized using 1H,1H,2H,2H-Perfluorooctyltriethoxysilane (98%) purchased
from Sigma-Aldrich. After silanization, the Petri dishes were used as a crystal-
lization platform and for sample collection. The dispersed phase (DP) was a
glycine solution saturated at room temperature (24±1 ◦C); therefore the glycine
content was approximately 25.4±0.5 g glycine/100 g water [83]. One drop of
the generated emulsion was dispensed directly into the glass Petri dish which
had a pre-dispensed layer of the continuous phase (CP) (0.5-1.5 mm nominal
thickness), placed on a hotplate (Thermo Scientific CIMAREC) set between
45 and 85 ◦C. The temperature of the CP in the Petri dish was measured with
a thermometer (Lutron TM-914C with a thermocouple) and is listed in Table
6 of Appendix B. Imaging of the process (always carried out at the center of
the Petri dish to eliminate any potential meniscus effects) was performed with
a high-speed digital camera (Basler pI640) mounted onto a stereomicroscope
(Leica MZ16). An Olympus LG-PS2 light source with a ring light was used
for illumination. A silicon wafer was placed under the glass Petri dish for im-
proved contrast. A schematic of the experimental setup is provided in Figure
10. Nine experiments a 3x3 matrix of initial droplet diameters (d0) and film
thicknesses (h f ) - were performed at a heating temperature of 65 ◦C in order to
investigate the effect of droplet size and shrinkage rate (controlled by film thick-
ness) on the outcome of spherical crystallization in the droplet populations, and
four additional experiments were performed to shed light on the effect of tem-
perature, at 45, 55, 75, and 85 ◦C. Each experiment was repeated at least three
times, and each trial typically included at least 100 droplets. All experiments
were imaged at 1 frame per second time resolution. Microscopic image analysis
was performed for droplet and SA size distribution, nucleation, and morphol-
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ogy statistics. Structural information of the SAs was acquired by FE-SEM, as
described in Chapter 2.
Figure 10: Schematic of the experimental setup used to monitor the crystalliza-
tion of droplet populations.
3.3 Results and Discussion
The experimental conditions and the main outcome - the fraction of Mor-
phology I SAs among the crystallized droplet population - are summarized in
Table 2, while the effects of shrinkage rate and droplet size on the outcome of
the process at a heating temperature of 65 ◦C are given in Figure 11. Briefly, at a
fixed temperature, faster shrinkage rates (obtained in thinner films) and smaller
initial droplet sizes favored the formation of a higher fraction of Morphology
I SAs. On the other hand, this fraction exhibited an apparent maximum (at an
intermediate temperature), on increasing temperature at fixed droplet size and
film thickness.
In order to understand these observations, the progression of the crystalliza-
tion process in the dispensed droplets was examined. Precise measurements
of droplet size were conducted from dispensing until the onset of crystalliza-
tion for at least 15 droplets per trial to determine how droplets shrank as water
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Table 2: Summary of the experimental conditions used, along with shrinkage
times, shrinkage rates and the percentage of Morphology I SAs. #: experiment
label; d0 : initial droplet diameter; dA : SA diameter; T : heating temperature;
h f : film thickness; ts : shrinkage time; d′ : shrinkage rate (see text for further
elaboration on shrinkage); fI : observed fraction of Morphology I SAs among
the crystallized ensemble.
# d0 dA T h f ts d′ fI
µm µm ◦C mm s nm/s
1 53±3 39±2 65 0.5 62±2 220 0.99±0.00
2 53±3 39±2 65 1 1060±323 13 0.92±0.07
3 53±3 39±2 65 1.5 1637±459 8.6 0.61±0.24
4 85±10 62±7 65 0.5 88±9 260 0.96±0.01
5 85±10 62±7 65 1 2369±578 9.8 0.67±0.10
6 85±10 62±7 65 1.5 4074±1492 5.6 0.47±0.15
7 165±5 118±5 65 0.5 84±10 560 0.90±0.04
8 165±5 118±5 65 1 3130±1190 15 0.66±0.07
9 165±5 118±5 65 1.5 6055±2269 7.8 0.41±0.08
10 85±10 62±7 45 1 13500±900 1.7 0.48±0.05
11 85±10 62±7 55 1 7728±1883 3.0 0.64±0.07
12 85±10 62±7 75 1 2542±964 9.0 0.32±0.09
13 85±10 62±7 85 1 1500±180 15.0 0.28±0.06
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Figure 11: The fraction of Morphology I SAs obtained at T=65 ◦C under differ-
ent conditions. The thicker the film (which leads to a lower shrinkage rate), and
the larger the initial drop diameter, the lower the fraction of Morphology I (i.e.
complete) SAs.
evaporated (a visual example is provided in Figure 12). It was found that in
all cases, droplet diameter (d) decreased linearly with time (Figure 12b), as
d(t) = d0− d′t where d′ is the (measured) shrinkage rate, and d0 is the dis-
pensed (initial) diameter of the droplet. At a fixed temperature, shrinkage rate
depends on the thickness of the continuous phase film containing the droplets,
and is determined by the convective and diffusive transport of water through
this film and into the ambient environment. While nominally constant ambient
conditions - room temperature (∼24 ◦C) and relative humidity (∼57 %) - were
maintained throughout our experiments, complete elimination of environmen-
tal fluctuations, such as those due to ambient air circulation, was not feasible.
Therefore, to circumvent this challenge whilst retaining analytical rigor, mea-
sured shrinkage rates are used in the discussions below, with the understand-
ing that these relate in a straightforward, quantifiable way to film thicknesses
under highly controlled processing conditions typical in pharmaceutical manu-
facturing. An example of this relationship for our experiments is provided in
Appendix B.
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Figure 12: a) An image sequence of the droplet shrinkage process with a film
thickness of 0.5 mm and T =65 ◦C. b) Droplet size measurements over time un-
der different film thickness conditions. c) Final droplet diameter (SA diameter)
as affected by the film height and initial droplet diameter for the 13 experiments.
Droplets shrink by roughly the same extent under all conditions: dA =0.73d0 .
Next, the diameter of the Morphology I SAs was compared to the dispensed
diameter of the corresponding droplets from which they were formed. Interest-
ingly, as shown in Figure 12c, it was found that under all conditions, droplets
shrank to roughly the same extent. In all cases, final SA diameter was ∼73 % of
the dispensed droplet diameter, implying, under the assumption that no glycine
leaves the shrinking droplets, that there is a limiting concentration (and there-
fore, a ’critical’ supersaturation Sc) beyond which shrinkage practically stops.
This phenomenon of a limiting supersaturation has also been reported in previ-
ous studies [84], [199] and can be attributed to the dramatic drop of diffusivity
in glycine solutions upon reaching this particular supersaturation level [198].
Moreover, it was also observed that single crystals or incomplete SAs (i.e. Mor-
phology II) tended to crystallize when nucleation occurred in droplets before
they reached this critical size. These observations imply that the attainment of
the critical supersaturation (Sc) corresponding to this critical size is necessary
for spherulitic growth to occur, which, in turn, can lead to the formation of com-
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plete SAs. Previous studies also cite high supersaturation and severely limited
diffusion as being essential to the growth of spherulites. A comprehensive re-
cent theoretical and computational study by Gra´na´sy et al. proposed that at high
concentrations, the rotational and translational diffusivities of a solution are de-
coupled, and their ratio (χ = Drot/Dtr) decreases sharply as supersaturation is
increased, which results in an enhancement of misoriented grain growth, lead-
ing to a spherical shape at larger length scales [193]. This transition between
single crystalline and spherulitic growth of an increasing degree of branching
(i.e. an increasingly spherical shape) with an increasing supersaturation was
also observed in experimental studies [209]–[211]. As mentioned above, only
SAs that grew into complete, compact spheres were classified as ’spherulitic’
(Morphology I) and all other morphologies were classified as Morphology II.
Putting these pieces of evidence together, it can be hypothesized that droplet
size and shrinkage rate take part in an interplay of two related phenomena;
firstly, as droplets shrink and the concentration of glycine in a droplet increases,
supersaturation is achieved and increases over time, and secondly, for supersat-
uration S > 1, nucleation occurs in each droplet at a finite, non-zero rate J .
Therefore, as a droplet shrinks, there is a finite (and increasing) probability for a
nucleation event to occur in that droplet before it reaches the supersaturation Sc
required for spherulitic crystal growth. Thus, according to this line of reason-
ing, when a droplet reaches this critical supersaturation before the occurrence
of a nucleation event, a Morphology I SA is obtained. On the other hand, if a
nucleation event occurs before the critical supersaturation is reached within a
droplet, a Morphology II SA will be obtained, the exact morphology depending
on the conditions within the droplet. Figure 13a shows a schematic of this pic-
ture of crystallization in this microfluidic emulsion-based system, while 13b-d
display SEM images of the different possible particle morphologies. The ef-
fect of droplet size and shrinkage rate can now be explained with the arguments
presented above by noting that smaller shrinkage rates (for example by using
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thicker oil films) lead to correspondingly slower rates of supersaturation gener-
ation, while larger droplet volumes are associated with a higher probability of a
nucleation event at a given supersaturation level.
Figure 13: a) Schematic of the SA formation process. There are two possible
outcomes: 1) Droplet reaches critical supersaturation before nucleation. This
leads to the formation of Mophology I SAs. Once formed, the SA might go
through an ’aging’ process, in which its surface transitions from a smooth to
a coarse structure, as seen in the previous chapter. 2) A nucleus forms within
the droplet before it reaches critical supersaturation, which leads to crystals of
Morphology II. b-d) SEM micrographs of different agglomerate morphologies
obtained from our experiments: b-c) ’smooth’ and ’coarse’ complete SAs; d)
single crystal.
Next, to model this process quantitatively, the following question has to be
asked: what is the probability of nucleation within a single droplet before it
reaches Sc, the critical supersaturation required for spherulitic growth? If, at the
time required for droplets to reach critical supersaturation (ts), the probability
of a nucleation event within a droplet is low (or conversely the probability of no
nucleation is high), a majority of Morphology I SAs can be expected to form
from the droplet population. In other words, if the above hypothesis describes
the process adequately, it can be expected that the probability of no nucleation
(P0) in a droplet at ts to corresponds, albeit roughly, to the fraction of Morphol-
ogy I SAs in a droplet population. A model to describe the stochastic nucleation
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within small droplets with a time-varying supersaturation was formulated by
Goh et al. [169] In this model, the evolution of Pn(t), the probability of n nucle-
ation events in a droplet, with time follows the following differential equations:
dP0
dt
=−κ(t)P0(t) P0(0) = 1 (3.1)
dPn
dt
=−κ(t)[Pn−1(t)−Pn(t)] Pn(0) = 0 n= 1,2... (3.2)
where κ(t) is the nucleation rate in a single droplet, i. e.
κ(t) = JV (t) (3.3)
Here, J is the nucleation rate (a function of S(t), the time-varying supersatura-
tion) and V is the volume of the droplet as a function of time. In this system,
Morphology I SAs grow rapidly in ∼0.1 s [199], and Morphology II crystals
typically finish growing within a second; these growth times are far shorter than
typical shrinkage times of >100 s. Therefore, it can be assumed that only one
nucleation event occurs within a droplet - an assumption borne out in the exper-
iments. This, in turn, implies that P0(t) adequately describes the process. By

















In order to compute P0(ts), t = 0 in the above integral is taken as the time at
which the shrinking droplet reaches S = 1, and ts is set to be equal to the time
when the droplet stops shrinking. This equality assumes that Sc is very close
to the final supersaturation attained by the droplets, which can be justified by
noting that as mentioned above - the reduction in diffusivity arresting shrink-
age [198] also facilitates spherulitic growth [193]. In this model, the measured
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where 0.73d0 is the average final size of the droplets (see discussion above).To
evaluate the integral in the exponent, classical nucleation theory was applied to








where A is a pre-exponential factor, described as the diffusion-limited rate of
nucleation (in this study A is a fitted parameter, see discussion below), S is the
supersaturation expressed as the ratio of the glycine activity relative to its value





where v is the molecular volume (assumed to be spherical for glycine with a
diameter of 0.53 nm [162]), σ is the interfacial tension between the nucleus
and the solution, k is the Boltzmann constant, and T is the absolute temperature.











where dm is the aforementioned molecular diameter, nCr =1575.3 g/L is the
solid density of glycine [213], and aS is expressed in units of g/L. The activity
coefficients of glycine at various temperatures were obtained from AspenPlus
VLE simulations via the built-in UNIFAC model. Simulated activity data at 25
◦C were validated with those reported by Na et al [214]. The calculated values
of B and σ under the temperatures used in this study, and the polynomial fit
used in the calculations are presented in Table 6 and Figure 38 of Appendix B
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respectively. The solubility of glycine in water [83] and the density of aqueous
glycine solutions [215] were obtained from existing literature. By measuring






where d(t) = d0 − d′t. Knowing the initial concentration of glycine in the
droplets, V (t), and the simulated relationship between concentration and ac-
tivity, S(t), and hence, J(t) and P0(t) can be obtained. Ultimately, in order to
obtain P0(t) at a given temperature from this model, only two measured param-
eters, d0 (initial droplet diameter) and d′ (linear droplet shrinkage rate) need to
be specified. P0(t) was evaluated until ts for all experimental conditions.
The simulation results and the corresponding observed Morphology I frac-
tions for T = 65 ◦C are compared in Table 3. The value of the pre-exponential
factor A= 2×1012m−3s−1 at T = 65 ◦C was obtained by nonlinear least square
regression performed inMATLAB on the results of all 9 experiments at this tem-
perature. The calculated trends from the model are generally in a good agree-
ment with experimental trends. Figure 14 shows three simulated P0(t) and S(t)
curves from three selected experimental conditions along with images from ex-
perimental runs. In the case shown in Figure 14a (and corresponding image in
Figure 14d), d′ is high, and d0 is small (experiment 1, Table 2). Here, P0(ts) is
very close to 1, which indicates that there is a low probability for a nucleation
event to occur before droplets reach critical supersaturation, leading to the ma-
jority of Morphology I SAs in this case. This is in good agreement with the
experimental observations, where ∼99% of the droplet population consists of
Morphology I SAs. Figure 14b and 14e shows a case where d′ is low and d0 is
large (experiment 9, Table 2). The calculated P0(ts) value of 0.33 indicates that
Morphology I SAs will be a minority in this sample, which is consistent with the
experimental result of fI ∼0.4. In the simulation shown in Figure 14c, droplet
size is increased drastically (to ∼600 µm); thus P0 drops to nearly zero well be-
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fore ts , which indicates that all droplets will likely nucleate before they reach Sc
and yield non-spherulitic, faceted crystals. This prediction is well borne out in
the corresponding experiment, shown in Figure 14f. Further validation comes
from the fact that the smaller satellite droplets co-generated with their larger
counterparts, in fact, yield the few Morphology I SAs that can be observed on
Figure 14f.
Table 3: Comparison of the simulated P0 (ts ) values (i.e. the probability of no
nucleation occurring within a droplet before it shrank to its limiting diameter)
to the fraction of Morphology I SAs at T=65 ◦C. The model accurately captures
the overall trends.
# d0 dA d′ P0(ts) fI
µm µm nm/s
1 53±3 39±2 220 1 0.99±0.00
2 53±3 39±2 13 0.99 0.92±0.07
3 53±3 39±2 8.6 0.99 0.61±0.24
4 85±10 62±7 260 1 0.96±0.01
5 85±10 62±7 9.8 0.93 0.67±0.10
6 85±10 62±7 5.6 0.89 0.47±0.15
7 165±5 118±5 560 0.99 0.90±0.04
8 165±5 118±5 15 0.56 0.66±0.07
9 165±5 118±5 7.8 0.33 0.41±0.08
These case studies show that our model describes the overall trends rather
accurately. There are, however, more subtle implications of the model that can
translate into a further understanding of this process. In the model, as mentioned
above, there are two parameters that determine P0(ts) at a given temperature d′
and d0 . Firstly, the effect of d′ is examined, where intuitively one can rea-
son that since no nucleation events in a droplet are required before reaching Sc
, the larger the d′ , the better. However, increasing shrinkage rates also im-
ply decreasing shrinkage times, thus implying steeper rates of supersaturation,
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Figure 14: The competition between time varying supersaturation S(t) and
P0(t), the probability of no nuclei forming within a droplet over time, for three
selected conditions. Data for P0(t)were obtained from the simulations described
in the text, while S(t) data were based on experimental measurements. If S
reaches the critical supersaturation required for spherulitic growth, Sc , before
the onset of nucleation, a certain fraction of Morphology I SAs form within the
ensemble. This fraction corresponds to the value of P0 at the time point when
S reaches Sc . a) and d) d0 =53 µm, h f =0.5 mm and T =65 ◦C; b) and e) d0
=165 µm, h f =1.5 mm and T =65 ◦C; c) and f) d0 =600 µm, h f =1 mm and
T =65 ◦C. The model accurately describes experimental trends. CSZ: critical
supersaturation zone.
and concomitantly larger nucleation rates at comparable times. The variation of
P0(ts) as a function of d′ at a fixed initial droplet size is therefore worth examin-
ing further, and model simulation results are shown in Figure 15a. These results
do in fact point to a nonlinear increase in P0(ts) with d′ , with a region of sharp
increase followed by a plateau. The simulations therefore recommend operation
at the cross-over point between the two regimes, beyond which there are dimin-
ishing returns on increased shrinkage rates, especially for the smaller droplet
sizes. Next, the effect of droplet size, d0 , is examined via a similar analysis.
At fixed shrinkage rate, the larger the droplet, the larger ts and V , but again,
J will be comparably smaller at each time point since S increases comparably
slowly. Results shown in Figure 15b demonstrate that the larger the droplet size,
the smaller P0(ts), and the lower the expected fraction of Morphology I agglom-
erates from a corresponding experiment. Collectively, the above considerations
imply that at a given shrinkage rate, there might exist a critical droplet diameter,
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Figure 15: a) The simulated effects of initial droplet size d0 and linear shrinkage
rate d′ on P0(ts), the probability of no nucleation before shrinkage is complete;
b) The effect of droplet diameter at a constant shrinkage rate, all at T =65 ◦C.
It can be seen that at any given d0 , the largest shrinkage rate gives the highest
P0(ts) value (i.e. the highest expected fraction of Morphology I SAs in the en-
semble). Similarly, at any given shrinkage rate, as initial droplet size increases,
P0(ts) decreases, eventually reaching ∼0 beyond a certain critical diameter dc
(e.g. in the case of d′ =10 nm/s, the 280 µm droplets are above dc ).
dc , above which no Morphology I SAs can be obtained from the system. To
calculate this value, P0(ts) can be simply set to ∼0 (e.g. 0.001) and for a cho-
sen d′ , dc can be obtained from the model. In fact, the choice of d0 for Figure
14f was based on these simulations, and led to an SA population that consisted
almost exclusively of Morphology II crystals. In principle, the same treatment
for a decreasing d′ could be used to obtain a critical value for shrinkage rate d′ ,
but reducing the rate of evaporation is generally unfavorable from a productivity
perspective. On the other hand, while increasing d′ is favorable for the produc-
tion of Morphology I SAs, the experimental apparatus used will necessarily set
upper limits on d′ . Therefore, one could imagine a scenario in which a solute
has a high enough nucleation rate before Sc is reached to completely preclude
spherulitic growth at droplet sizes achievable by microfluidic devices. Finally,
it is also noted that the generality of this model means that it can describe the
crystallization behavior of solutes in which, for example, the functional form of
J(S) is different from that used in Equation 3.6 above.
The experimentally observed effect of temperature at a given film thickness
and initial droplet diameter is a more complex issue. The experimental results
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in Table 2 (experiments 10-13) suggest an optimal intermediate temperature at
which the highest fraction of Morphology I SAs is produced under otherwise
identical conditions. In order to explain this trend, the behavior of the two pa-
rameters in the nucleation rate expression must be examined: while B can be
calculated in straightforward fashion as outlined above, A is a rather sensitive
parameter that is a complicated function of temperature and molecular proper-
ties [23]. In this study, A was fitted to the results of all experiments at h f =1 mm
and d0 =85 µm (see Figure 39 of Appendix B). Knowing A(T ) now enables the
prediction of P0(ts) at any given point in the (d0 , d′ ) parameter space at a given
temperature. Figure 16 shows illustrative simulated surfaces of P0(ts) as a func-
tion of d0 and d′ at three representative temperatures within the range studied.
It is instructive to observe that at each temperature, there exists a region on this
map where P0(ts) ∼1, adjacent to a fairly steep intermediate region, ultimately
leading to a domain where P0(ts)∼0. It would generally be desirable to operate
a crystallization process well within in the P0(ts)∼1 region. The most practical
way to achieve this is to use the highest possible shrinkage rate (and thus lowest
practical film thickness) at a given temperature and droplet size. Next, to ex-
plain the optimal temperature reported in Table 2, note that the shrinkage rate
at a given film thickness increases with temperature, and while film thickness
is the tunable processing parameter, the shrinkage rate is what ultimately influ-
ences the outcome of the process. If the outcomes of experiments conducted
at h f =1 mm and d0 =85 µm at different temperatures (#5, 10-13 in Table 2)
are compared to simulated P0(ts) values using a shrinkage-rate temperature re-
lationship fitted to the measured shrinkage rates (see Figure 40 of Appendix B),
the experimentally observed trend is recovered (Figure 16d).
Finally, the validity of the model was further tested in the following way.
Three SA sizes were selected as targets under two selected conditions of d0 and
h f within the previously described range. Measured fI and simulated P0(ts) data
were compared to determine whether or not the model proved to be accurate in
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predicting the superior processing conditions (i.e. which condition produced
the higher fraction of Morphology I SAs). The experimental conditions and the
results are presented in Table 4. It can be seen that the model provided correct
predictions in all three cases, even though all the experiments were performed
in the steep intermediate range of P0(ts) described above.
Figure 16: a-c) Simulated surface plots of P0(ts) in the two-dimensional d0 -d′
space, at a) T =50 ◦C, b) T =60 ◦C, and c) T =70 ◦C. Note the expansion of the
low P0(ts) region with increasing temperature. d) Simulated P0(ts) compared
to experimental results for d0 =85 µm and h f =1 mm at different temperatures
(shrinkage rate-temperature relationship used in the simulations is provided in
Figure 40 of Appendix B). The model qualitatively captures the experimentally
observed trends.
3.4 Concluding Remarks
The work presented in this chapter build has shed light on the dynamics and
morphological outcomes in the thin-film spherical crystallization of glycine.
Specifically, the effects of droplet size, shrinkage rate, and temperature were
studied with the aim of understanding and delineating crystallization conditions
that ensure spherulitic crystal growth in individual droplets, ultimately yielding
compactly packed spherical crystal agglomerates (SAs). Experiments indicate
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Table 4: Summary of the validation exercise to test the predictive capability of
the model.
# d0 dA T h f d′ P0(ts) fI
µm µm ◦C mm nm/s
V1 73±5 53±4 55 0.8 4.7 0.98 0.91±0.03
V2 73±5 53±4 75 1.3 6.7 0.91 0.26±0.05
V3 110±8 81±6 60 0.6 31 0.98 0.94±0.03
V4 110±8 81±6 50 0.9 3.3 0.91 0.71±0.07
V5 157±9 110±7 65 0.8 13 0.87 0.78±0.05
V6 157±9 110±7 70 0.65 51 0.95 0.91±0.01
that a smaller initial droplet diameter, a higher linear shrinkage rate, and a lower
temperature favor the formation of complete SAs, while the opposite leads pri-
marily to incomplete spherical agglomerates and faceted single crystals. The
observations were analyzed within the framework of a simple physical model
based on classical nucleation theory and the theory of non-homogeneous Pois-
son processes, which accurately captured the overall trends. According to this
model, smaller droplets and faster shrinkage rates (in thinner films) favor the
formation of compact SAs at a given temperature, and lower temperatures gen-
erally favor compact SA formation at a fixed drop size and shrinkage rate. The
next chapter will focus on implementing these insights in a continuous, scalable
thin-film evaporator.
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4 Continuous Emulsion-based Crystallization
The previous two chapters demonstrated the production of unprecedentedly
uniform SAs with a great reduction in processing time (as compared to conven-
tional batch systems). However, the setup presented above couples continuous
emulsion generation with batch evaporation, a shortcoming that was highlighted
in a recent review that called for new, continuous pieces of equipment [216].
Therefore, it would be desirable to shift from a semi-batch crystallization step
to a continuous one to be able to fully exploit the advantages of continuous
microfluidic emulsion generation and to enhance production rates by accommo-
dating a larger flux of emulsions from several emulsion generators.
This chapter presents a continuous emulsion-based crystallization platform
based on the concept of the belt evaporator. Two prototypes were fabricated.
The first prototype serves as a proof-of-concept whilst gaining understanding
of the key parameters that have to be controlled. The second prototype was
fabricated to use the gained understanding to test ideas for improvement. It was
found that these apparatuses could produce good quality glycine SAs at rates on
the order of 1-10 g/day. As the second prototype has a volumetric footprint of
only ∼10 L, it can be straightforwardly scaled up to industrially relevant rates
by parallelization.
4.1 Prototype I: a Proof-of-concept
A conceptual schematic of the setup and is shown on Figure 17, while a
model and a photograph of the prototype is shown on Figure 18: the key idea is
a heated conveyor belt that has been adjusted to the requirements of emulsion-
based crystallization. A continuous stream of the emulsion is dispensed onto
one end of the belt, which then conveys the emulsion over a heated region to fa-
cilitate evaporative crystallization. Residence time is adjusted by adjusting the
speed of the belt so that at a given operating temperature all of the droplets crys-
tallize by the time they reach the outlet end, where a scraper is used to collect
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the product.
Figure 17: A conceptual schematic of the continuous crystallizer. Emulsions
are dispensed on a heated conveyor belt, where solvent is evaporated from the
droplets, which, in turn, leads to the formation of SAs. A scraper is used to
collect the product.
4.1.1 Experimental
All parts were purchased from McMaster-Carr. The setup is mounted on struc-
tural framing and custom-made connecting elements. In this setup, a 2” diam-
eter (6” width) conveyor belt pulley - coated with 1 mm of silicone rubber for
better grip - is driven by a 0.6 rpm (maximum) DC gear motor equipped with a
speed controller, while the other pulley is a 2” shaft. The two pulleys were hori-
zontally aligned and their centers were mounted 50 cm apart, which allowed for
the adjustment of residence times between 5 and 40 minutes. The belt is made
of 6” wide, 0.1 mm thick stainless steel shim stock welded into a loop, and is
tensioned manually. The heater is a 18”X6”, 4 mm thick aluminum sheet that
has a 12”X6”, 720 W heating strip attached to its bottom side, while the top
side is in direct contact with the belt. Temperature is controlled by a PID con-
troller that gets feedback from a thermocouple attached to the aluminum sheet
∼1 cm from the edge of the heating strip. The materials for preparing monodis-
perse microfluidic emulsions of an aqueous glycine solution in dodecane are
identical to those used in the previous two chapters, as are the characterization
techniques used on the final product. To generate the emulsions, however, a
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Figure 18: a) To-scale model of prototype, top view with key dimensions in-
dicated; b) photograph of the prototype. The important parts are marked with
numbers: 1) syringe pumps & microfluidic device; 2) inlet tube; 3) heated con-
veyor belt; 4) PID temperature controller; 5) scraper; 6) gear motor and speed
controller.
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robust flow-focusing PMMA emulsion generator was used instead of glass cap-
illary devices. These PMMA devices are essentially single-channel versions of
the high-throughput emulsion generator developed by Conchouso et al. [217].
The continuous and dispersed phases were infused using syringe pumps similar
to those used in the previous chapters. The generated emulsions were then dis-
pensed through an OD=1/16” and ID=0.01” PTFE tube on the belt at the start-
ing point of the heating element (∼1” from the center of the pulley) to maximize
useful contact time.
4.1.2 Results and Discussion
Belt temperature at several locations was measured with a thermocouple in order
to determine the temperature profile of the belt under the three control tempera-
tures used for demonstration (35 ◦C, 55 ◦C, 75 ◦C). These profiles are presented
on Figure 19. As can be seen, temperatures fluctuate over relatively wide (but
distinct) ranges, with the edges and the inlet side being slightly cooler than the
central areas. Although for a precise industrial device these fluctuations will
have to be reduced (a few ◦C is considered acceptable in crystallization pro-
cesses [18]), they did not prove to be an impediment to the production of quality
SAs under any conditions. One industrially relevant SA diameter, ∼50 µm was
chosen for proof-of-concept studies. These could be obtained at a continuous
phase flow rate of 0.2 ml/min, and a dispersed phase flow rate of 0.02 ml/min.
A single stream of emulsion was used. The necessary residence times for com-
plete crystallization for the three temperatures used were determined to be ∼30
min (35 ◦C), ∼15 min (55 ◦C) and ∼6 min (75 ◦C). The width of the dispensed
stream varied with belt speed between ∼1 and ∼5 cm, which means that a 6” belt
would allow for 3 parallel streams at the lowest belt speed setting. The product
was collected using a stainless steel scraper for further analysis, and the belt was
stopped and manually cleaned after each turnaround to simulate a cleaning and
drying mechanism that would be present in an industrial apparatus.
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Figure 19: Belt temperature profile of the prototype on the heated section (there
is an 1” un-heated section between the heater and each pulley). The inlet side is
on the left of the figure. Measurements were taken at the nodes of a 1” mesh on
the 18”X6” section. Note the relatively large fluctuations and the slightly lower
temperatures at the edges and the inlet side. These fluctuations did not have a
noticeable effect on the quality of the product.
Figure 20a-c shows SEM images of the product obtained from the scraper
under the three different temperatures, as compared to the product from semi-
batch crystallization (obtained by dispensing a drop of emulsion onto the sta-
tionary belt at a particular temperature setting and waiting until crystallization
finishes). The images show that the SAs obtained from the scraper are indistin-
guishable in their quality from their semi-batch counterparts, thus proving the
viability of the concept. Figure 20d presents similar results obtained from an
experiment performed with an emulsion generated in batch (crystallization per-
formed at 80 ◦C control temperature), which points out that this setup can also
compliment traditional methods of emulsification. If 0.02 mL/min (20 µL/min)
is taken as a benchmark for dispersed phase flow rate, a glycine solubility of
24.41 g/100 g water [83] and a solution density of ∼1.1 g/mL is assumed [215],
the nominal productivity of this prototype is ∼5.8 g/day.
Although this prototype - tested on a robust, well-studied emulsion-based
crystallization process - proves that the apparatus is conceptually viable, three
major aspects need to be improved. Firstly, dispensing the emulsion directly
on the belt results in a film thickness that is entirely controlled by the spreading
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Figure 20: Comparison of SEM images of 50 µm glycine SAs produced by the
prototype and the semi-batch method described in Chapter 2 under different con-
trol temperatures: a) 35 ◦C, b) 55 ◦C, c) 75 ◦C. Left column: semi-batch SAs,
right column: SAs collected from the scraper. The scale bar is valid throughout
a-c; d) Comparison of SAs obtained from the semi-batch method (left) and from
the scraper (right) when batch emulsification was used at a heater temperature
of 80 ◦C and a residence time of 6 minutes. As can be seen, there is no qualita-
tive difference between the SAs obtained from the semi-batch method and those
obtained from the prototype.
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properties of the continuous phase on the belt material. A nominal film thickness
for such cases can be roughly estimated if the contact angle, θc , between the
substrate and the continuous phase is known, e.g. by first estimating the width of
the dispensed stream by the θc /2 method [218] and then using the h f ·w ·vb =Qt
relationship to calculate the nominal film thickness. Here, w is the estimated
stream width, vb is the belt velocity and Qt is the total flow rate of the emulsion.
Moreover, belt irregularities (such as minor folds in the shim stock) resulted in
a tendency of continuous phase drainage to the side. Therefore, there’s a need
to control the stream width and the film thickness, perhaps with the horizontal
confinement of the film (i.e. division of the belt into trenches of controlled
width and height). Secondly, a more precise control of the environment, i.e.
temperature and humidity is needed (which requires an improved heater design
and an enclosure for the setup). Finally, it would be desirable to reduce the
volumetric footprint of the unit to increase productivity per unit volume. A
second prototype built to implement these improvements is presented in the next
section.
4.2 Prototype II: an Improved Design
4.2.1 Experimental
Amodel and a photograph of the prototype is shown in Figure 21. All parts were
purchased from McMaster-Carr, unless indicated otherwise, and the apparatus
was fabricated in a machine shop. The setup is enclosed in a 1” thick acrylic box
that has inner dimensions of 557x117x60 mm. The two 1/2” shafts that hold the
belt are placed 20” apart, one of which is attached to a 5 rpm (maximum) DC
gear motor. The belt was custom made of 2” wide, 1 mm thick silicone rubber,
and a strip of 1/2” wide oil-resistant tape (3M-444) was placed on each side to
create a 1” (∼25 mm) wide trench of ∼100 µm depth. The heater is an 18”x2”
mineral insulated strip heater custom made by PTI Singapore. This heater has
a maximum output of 1000 W, but is operated at 30%. The heater is suspended
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Figure 21: a) to-scale model of prototype with main dimensions indicated; b)
schematic of belt setup with photograph of emulsion inlet and film at the 38 ◦C
experiment, as listed in Table 5; c) photograph of the second prototype: 1) belt
with heater; 2) emulsion inlet; 3) emulsion generator & syringe pumps; 4) gas
outlet (inlet on the other end); 5) gas flow controller; 6) temperature controller;
7) gear motor.
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below the belt so that the belt slides on its surface, giving a heated length of ∼45
cm. Heating temperature is controlled (with an accuracy of 1 ◦C) by a Watlow
EZ-zone PID controller (also purchased from PTI Singapore) that gets feedback
from a thermocouple attached to the surface of the heater. Pure nitrogen gas is
flown through the enclosure to flush out the evaporated solvent. The flow rate
of this gas is controlled by a mass flow controller (SMC PFM750S, purchased
from RS Components Singapore), and it is set to 4 L/min, which corresponds
to a gas residence time of 1 minute. The emulsions are dispensed through an
OD=1/16” and ID=0.01” PTFE tube. The stream of emulsion was split into two
with a T-junction so that the resulting two inlets could provide a more uniform
distribution of the emulsion on the belt. The two inlets were then placed ∼6 cm
from the input end of the belt, which leaves a utilizable belt surface of ∼45 cm
x 2.5 cm. A stainless steel scraper was used for sample collection. The scraper
was placed in an aluminum box to prevent dodecane leakage and to aid sample
collection. Emulsions were generated in the PMMA device described in the
previous section.
4.2.2 Results and Discussion
Four preliminary experiments were carried out to gain insights about feasible
operating ranges of the setup. First, TB , the surface temperature of the belt as
a function of T , the set temperature was measured with a thermocouple at the
two edges and the center of the belt at every 5 cm of heated length at the highest
speed setting, ∼24 cm/min (Figure 22a). Figure 23 shows TB as a function of T
. It was found that the belt surface temperature only fluctuates within the 1 ◦C
measurement error of the thermocouple, a remarkable uniformity compared to
the previous prototype. Next, two experiments were carried out with a station-
ary belt (all trials in triplicate). First, to determine the minimum and maximum
nominal film thickness achievable, 2.5x2.5 cm segments of the belt were iso-
lated with oil-resistant tape, and pure continuous phase was dispensed at three
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Figure 22: a) Measurement of belt temperature as a function of heating temper-
ature b) the measurement of minimum and maximum film thicknesses with a
stationary belt; c) the measurement of crystallization times on a stationary belt.
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Figure 23: Belt surface temperature TB as a function of set temperature T .
The temperature of the belt fluctuated only within the measurement error of the
thermocouple (hence the lack of error bars).
belt temperatures, 38, 48, and 58 ◦C (roughly corresponding to three temper-
atures used in Chapter 3) until the segments filled up and overflowed (Figure
22b). It was found that a nominal film thickness of ∼80 µm is the minimal
amount that can fill up the channel, and overflow occurred at ∼160 µm. Subse-
quently, crystallization experiments were carried out in these segments (Figure
22c) at the three temperatures and the two extreme film thicknesses to determine
the time required for crystallization. These experiments used 50 µm agglomer-
ates (generated under QCP = 200 µL/min and QDP = 20 µL/min, identically to
the previous section), because these relatively small SAs are expected to form
slower - as shown in Chapter 3 - and can therefore be used to get a conservative
(upper) estimate of time required for crystallization. Figure 24 shows the results
of these measurements. Difficulties in imaging the crystallization process (due
to the glossy belt material and the fact that the distance between the belt and the
top of the enclosure is larger than the focal length of the available microscopes)
resulted in a large standard deviation of crystallization time results. Therefore,
twice the mean was taken as a minimum crystallization time when determining
feasible operating conditions. Since the flow rate of the emulsion and the film
thickness also determines an actual residence time, successful operation of the
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Figure 24: Crystallization time, tc , as a function of belt surface temperature TB
and nominal film thickness h f .
process requires this residence time to be more than the time required for crys-
tallization. Finally, from a productivity standpoint - since the dispersed phase
carries the crystallizing compound - a high volumetric ratio of dispersed to con-
tinuous phase would be desirable. Therefore, several semi-batch crystallization
experiments - similar to those presented in Chapter 2 - were performed to deter-
mine the minimum CP:DP volume ratio under which secondary agglomeration
- the tendency of agglomerates to stick together - is still negligible. This ratio
was found to be approximately 3:1.
Based on the fact that crystallization times at a nominal film thickness of 80
µm are less than half of crystallization times at 160 µm (an observation con-
sistent with the film thickness-evaporation time relationship seen in Chapter 3),
three total flow rates were selected for productivity measurements at the three
different belt temperatures and a fixed nominal film thickness of 80 µm. This
nominal film thickness is defined by the width of the trench, the total flow rate,
and the belt velocity (i.e. the residence time, as listed in Table 5). Flow rate
ratios were kept at CP:DP=3:1 to maximize productivity. The experiments were
run for 2 hours (each performed twice), and the crystallized sample was col-
lected and dried (overnight in a 70 ◦C oven) and weighed for productivity mea-
surements, while minute amounts of wet samples were collected and dried at
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room temperature for SEM analysis. The experimental conditions, along with
the results are summarized in Table 5. Productivities of up to 5.3 g/day were
Table 5: Summary of the experimental conditions and the outcome of the con-
tinuous crystallization runs. TB : belt temperature; Qt : total flow rate (always
at CP:DP=3:1; tr : residence time (always at a nominal film thickness of 80
µm); dA : average agglomerate diameter; Ye : experimental productivity; Yt :
theoretical productivity.
TB Qt tr dA Ye Yt
◦C µL/min min µm g/day g/day
38 40 23 73±5 2.1±0.2 2.6
48 65 14 70±4 3.3±0.2 4.2
58 95 10 56±4 5.3±0.3 6.2
measured, typically reaching ∼80% of the theoretical yield. SEM comparison
of the SAs obtained from the scraper to their semi-batch counterparts gives fur-
ther interesting insights into design criteria (Figure 25). As can be seen, samples
collected from the scraper contain a significant amount of broken SAs, as op-
posed to the purely spherical populations observed with the previous prototype.
These differences may arise due to two factors: firstly, the proof-of-concept
studies used a smaller SA diameter (<50 µm). Observational evidence suggests
that small agglomerates ’age’ less and have a more compact structure (e.g. see
Figure 5 of Chapter 2). This, in turn, results in less attrition during scraping
and sample collection. Secondly, although a CP:DP ratio of 3:1 is sufficient in a
semi-batch setup to reduce secondary agglomeration and undesirable interaction
between the droplets to an acceptable level, a scenario of a constantly moving
film might require a larger ratio. The optimization of a future industrial process
- be it pure crystallization or an advanced formulation, such as the one presented
in the next chapter - will require the adjustment of both the flow rate ratio and the
size and morphology of the generated SAs. While such optimization exercises
are beyond the scope of this study, the preparation for an industrial process will
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Figure 25: SEM images of SAs obtained from the second continuous crystal-
lizer at the three different belt temperatures, as compared to their semi-batch
counterparts. Left column: semi batch SAs; right column: SAs collected from
the scraper. a) 38 ◦C; b) 48 ◦C; c) 58 ◦C. The scale bar applies for all images.
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require a simultaneous control of flow rate ratio and droplet size, a feat achiev-
able through the design of microfluidic device geometry or the addition/removal
of continuous phase after emulsion generation.
4.2.3 Conclusions
In conclusion, this prototype demonstrated the continuous production of glycine
SAs on the ∼5 g/day scale. The following improvements were implemented, as
compared to the first prototype: 1) superior heater design provides a very uni-
form belt temperature; 2) the application of an inert flushing gas provides a
controlled atmosphere for the process whilst removing the evaporated solvent;
3) confinement of the dispensed emulsion to a trench provides an improved
control over film thickness; 4) the volumetric footprint of the entire apparatus
was reduced to ∼10 L. With this demonstration and with the experience gained
regarding the design criteria for continuous emulsion-based crystallization pro-
cesses, the stage is set for an industrial application. However, there are still
some challenges that need to be overcome before the first microfluidics-enabled
continuous crystallizer surfaces in the industry. Some of these challenges - such
as improving the yield of the process and the robustness of the device - are
purely a matter of design and fabrication, and will therefore not be addressed in
detail. On the other hand, challenges in designing robust spherical particles in
microfluidics and conceptual considerations for scale-up are of great relevance
to R&D scientists. Therefore, these ideas will be presented in the next chapter,
which discusses the future prospects of this thesis.
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5 Future Prospects
This chapter will give the reader of the overview of possible future paths
that this thesis opened up for exploration. First, advanced drug-excipient for-
mulations with an exquisite control of API polymorphism are explored in the
context of an ongoing study. Next, the path towards the industrial application
of microfluidic emulsion-based crystallization platforms is laid out. Finally, in-
teresting fundamental directions that could be explored with these platforms are
summarized.
5.1 Advanced Microfluidic Formulations
While a pure, readily crystallizing API compound, glycine, is suitable for
the proof-of-concept studies presented in the previous chapters, industrial for-
mulations are rarely this simple. Firstly, due to the high potency of most new
API compounds, the final solid form often contains only a minute amount of
API crystals. This necessitates the co-formulation of actives with excipients
[219]. Secondly, APIs are often complex molecules that can pack into several
conformational polymorphs with very similar stabilities [43]. More often than
not, these polymorphs appear concomitantly, resulting in a product with incon-
sistent downstream properties. Therefore, there is a great need for formulation
methods that can simultaneously control polymorphism and ensure consistency
in the size, shape, and composition of the solid form.
In a study currently in progress in our group - and the specifics of which
will be published elsewhere - ROY, a molecule exhibiting an extreme (and col-
orful) case of conformational polymorphism [220], was co-formulated with an
excipient into monodisperse ∼150 µm spherical particles using a microfluidic
thin-film evaporation platform similar to the one presented in Chapter 3. The
polymorphic outcome of crystallization could be tuned by changing the film
thickness of the continuous phase (and thereby, the rate of evaporation).
First, control experiments were carried out without the excipient. Generally,
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crystallization took 4-5 hours (even in the thin-film case), and emulsions were
comparatively unstable. Optical micrographs and SEM images of the resulting
particles are shown on Figure 26. As can be seen, particle morphology is in-
consistent, and polymorphs of two different colors (yellow and orange) form
concomitantly. The situation changed dramatically when experiments were car-
Figure 26: Pure ROY spherical agglomerates. As can be seen the morphology
and the polymorphic outcome of the product is inconsistent. a) and c): thick
film; b) and d): thin film.
ried out with the excipient. Firstly, overall crystallization times were reduced to
∼30-45 minutes (thin film) and 3 hours (thick film). Secondly, as shown in Fig-
ure 27 spherical particles of remarkable uniformity were obtained. Finally, and
most importantly, thin film experiments exclusively resulted in the crystalliza-
tion of one of the yellow polymorphs, and thick film experiments exclusively
yielded an orange polymorph.
Such systems, in which excipients enhance nucleation (manifested in the re-
duced crystallization times) and aid polymorphic control in co-formulation sce-
narios, can be anticipated to become widespread in microfluidics-based spheri-
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Figure 27: Co-formulated ROY-excipient spherical particles. By tuning the film
thickness, the polymorphic outcome of the process can be changed. a) and c):
thick film; b) and d): thin film.
cal crystallization techniques. Future work in this area will include the discovery
of new microfluidic drug-excipient co-formulation methods, and the application
of the discovered techniques to industrially relevant actives. There is a virtu-
ally infinite variety of additives and configurations that could be explored to
improve the structural or polymorphic outcome of the process, but for the sake
of brevity only one will be highlighted: recently our group has demonstrated the
co-formulation of an excipient with a hydrophilic and a hydrophobic API com-
pound into monodisperse spherical particles using microfluidic double emul-
sions [203]. Such advanced API-excipient co-formulations are of great interest,
because they can be expected to be the primary choice in potential industrial
applications.
5.2 Towards Industrial Application
The prototypes presented in Chapter 4 are suitable for the continuous pro-
duction of high quality SAs. However, there are two challenges that have to
be solved before the industrial application of such apparatuses. Firstly, while
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the production rate of ∼10 g/day is suitable for some small-volume compounds,
scaling it up by at least an order of magnitude would open up a host of other
opportunities.1 Secondly, some formulations, such as the one presented in the
previous section, require relatively thick continuous phase films (more than 0.5
mm) with precise control. Deeper trenches, and a dispenser that is flush with
the trench could enable the use of such film thicknesses. However, as the film
thickness increases, the influence of gravity becomes dominant over interfacial
forces [221], which could result in the drainage - and thereby the disruption of
the uniformity - of the film at the outlet end. Therefore, the confinement of
the film along the moving direction may be necessary for thicker films. The
following sections present tentative solutions to these two problems.
5.2.1 Scale-up
Increasing production rates is straightforward both conceptually and practically,
as parallelization is a well-known method for the scale-up of microfluidic sys-
tems [222]. However, the construction and operation of the bench-top proto-
types provided some valuable practical guidelines for scale-up. To start with, in
an industrial setup, high-throughput microfluidic emulsion-generation will be
necessary. Fortunately, several such technologies emerged recently, e.g. mas-
sively parallelized flow-focusing devices [217], microfluidic post arrays [223],
or emulsion generation driven by gradients of confinement [224]. The generated
emulsions (and therefore, the emulsion generators) will also have to be opti-
mized for the quality of the crystals and the productivity of the process - as seen
in Chapter 4. Since syringe pumps are limited by the volume of the syringes,
these emulsion generators will most likely be driven by continuous peristaltic
pumps. Next, to ensure consistent evaporation and crystallization times, a pre-
cise control over nominal film thickness will be necessary. Such control can be
achieved by changing the width of each ’trench’ (fabricated into the belt, rather
1Based on discussions with GSK personnel.
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than added with tape) so that a single stream of emulsion fills it up (i.e. the
width of the trench is less than the spread of the emulsion stream on the belt
material). In order to accommodate for systems requiring both long and short
evaporation times, industrial setups will likely have longer belts that are able to
move at a wide range of velocities. The material of the belt should be selected
based on two considerations: 1) it should possess a relatively high heat conduc-
tivity to ensure a uniform temperature, 2) it should be preferentially wetted by
the continuous phase to prevent droplets and SAs from sticking to the belt. A
single belt, contained in a single enclosure, will accommodate several parallel
trenches, thereby reducing the excess volume taken up by the enclosure wall.
Finally, the continuous unit will have to be integrated with downstream steps,
such as filtration and drying. To achieve such integration, the stationary scraper
will have to be complemented with a stream of flushing liquid that serves a
dual purpose: mobilizes the resultant powder for downstream processing, and
cleans the belt from residual particles. This flushing liquid will most likely be a
non-solvent that is miscible with (or identical to) the continuous phase.
5.2.2 Accommodating Thicker Films
As seen above, some formulations require relatively thick continuous phase
films with a precise control over the film thickness. The continuous thin-film
evaporator described above, however, only caters to processes that benefit from
higher shrinkage rates (and thinner films). Therefore, a need will inevitably arise
for continuous evaporator designs that are capable of handling thicker films. A
schematic of one such design is presented in figure 28. In this design, the belt is
compartmentalized into ’carts’. Initially, the emulsion is dispensed on a station-
ary belt until the first cart is filled to the desired level. Next, the belt moves so
that the dispenser jumps to the second cart. The carts are then conveyed as evap-
oration and crystallization progresses. Finally, as crystallization is finished and
the cart reaches the end of the belt, a stream of washing liquid flushes the parti-
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Figure 28: Schematic of a continuous evaporator design for systems that require
well-controlled and relatively thick continuous phase films.
cles from the carts to the next processing step. To allow for a higher throughput,
the carts could be ’parked’ outside the moving belt, and only re-enter when
crystallization is complete.
5.3 Fundamental Directions
As shown in Chapters 2 and 3, the on-line microscopic monitoring of crys-
tallization frommonodisperse emulsions enables the investigation of crystalliza-
tion dynamics in emulsion droplets. Based on these studies, it can confidently
be stated that a sufficient phenomenological understanding of the process has
been gained. However, as the individual phases of crystallization influence the
final quality of the product obtained, they all deserve further attention. Possible
future research directions in these fields are summarized in the sections below.
5.3.1 Nucleation
The investigation of nucleation frommonodisperse microfluidic emulsions should
be a top priority for future studies. Firstly, Chapter 2 hypothesizes that the rea-
son why the probability of no nucleation over time follows a compressed expo-
nential model is the interaction between droplets and crystallized SAs. While
this hypothesis is certainly backed by evidence, it might not explain the phe-
nomenon entirely. Recently, Sear pointed out that a compressed exponential
process may arise simply due to nucleation at a surface that changes irreversibly
with time [88]. With a bit of abstraction, this ’surface’ can be set to be equiv-
alent to changing conditions within the droplets in a crystallizing population.
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These changes in conditions can arise if the droplets still shrink after reaching
the ’critical’ size, albeit at an unnoticeably slow rate. To simulate one such case,
the model developed in Chapter 3 is invoked. It is assumed that a 100 µm droplet
at 59 ◦C shrank to dc - 73 µm - at an infinitely high rate, so that P0 remains 1 by
this point in time. Then, it is assumed that the droplet continues to shrink 5% of
dc (∼3.6 µm, i.e. within experimental measurement error) at a - very low - rate
of 1 nm/s. Figure 29 presents the progression of ln(P0) as the function of time
in this case. As can be seen, a compressed exponential model is recovered from
Figure 29: Simulated nucleation statistics in the case of continued slow droplet
shrinkage, along with a compressed exponential fit.
the simulated nucleation statistics. However, the evidence for interaction be-
tween droplets presented in Chapter 2 suggests that continued shrinkage alone
cannot account for the compressed exponential process. Therefore, further ex-
perimental investigation and modeling work will be needed to shed light on the
importance of these factors and their dependence on operating conditions (such
as droplet size, shrinkage rate, and temperature).
Secondly, influencing nucleation through additives is an invaluable tool when
dealing with compounds that behave in an undesirable way in their pure form.
Beside the drug-excipient co-formulation presented above, one could imagine
emulsion droplets laden with functional molecules or particles that template the
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nucleation of a desired polymorph, a technique often demonstrated in conven-
tional systems [32], [33], [38], [39], [85]. Furthermore, some solutes might
exhibit nucleation rates that are high enough to completely preclude spherulitic
growth in microfluidic droplets. Additives that either slow down nucleation or
provide conditions that favor spherulitic growth (such as an increased viscosity
[193]) could be used to improve chances of SA formation. On the other end
of the scale lie solutes that experience a dramatic reduction in nucleation rate
at high supersaturations, and end up sitting around in a glassy, melt-like state
indefinitely [225]. Investigation of additives that enhance the nucleation of such
solutes would obviously be beneficial for the process.
5.3.2 Growth
The growth of spherulites is a well-studied phenomenon in polymeric and metal-
lic melts [192], [193]. However, the difficulty of reaching concentrations con-
ducive of spherulitic growth and the extremely high growth rates have thus far
prohibited the in situ investigation of spherulitic growth in the context of small
organic compounds. With the methods presented in Chapter 2, such investiga-
tions become straightforward. In future studies, growth rates could be measured
as a function of processing parameters (most notably, temperature), types of
spherulitic growth could be observed (category I or II [193]) in different crystal-
lizing materials, and in sufficiently large droplets with sufficiently large shrink-
age rates, a switch between spherulitic and diffusion-controlled growth could
be observed [191] to precisely identify the concentration at which spherulitic
growth still proceeds. These experimental observations could then be comple-
mented with phase-field modeling [193] to extract physical parameters (such as
viscosity and rotational and translational diffusivities) in highly supersaturated
systems. If a sufficient amount of simulated and experimental data is amassed,
the prediction of the spherulite-forming tendency of small organic molecules
could eventually become possible.
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5.3.3 Aging
The final step of SA formation, aging, is very important because of its role in
influencing the structure of the SAs - which, in turn, affects their downstream
performance, as seen in Chapter 4. In Chapter 2 it was determined that this
phenomenon is a solvent-mediated phase transformation in the case of glycine.
However, observational and circumstantial evidence indicate that both the rate
and extent of aging are highly dependent on both SA size (smaller SAs age less,
e.g. see Figure 5 of Chapter 2) and temperature (higher temperature leads to
more and faster aging, e.g. see Figure 20 of Chapter 4). In light of these pieces
of evidence, it could be hypothesized that because the stochastic nucleation of
the α and the β polymorphs occurs at different rates, only in some droplets will
the α polymorph also nucleate before trapped water is completely evaporated
from the SA. These SAs then undergo solvent-mediated phase transformation,
while the SAs with no α-glycine nucleation remain un-aged. In a future setup,
a Raman microscope with tunable temperatures could be used to observe the
aging of SAs in situ. After a statistically significant amount of data has been
collected, a mathematical model similar to the one presented in Chapter 3 could
be formulated. This model could not only predict aging, but it could also yield
nucleation rate parameters for the two polymorphs at different temperatures, an
important piece of information currently not available in the literature.
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6 Conclusion
In conclusion, this thesis presented the start-to-finish development of a new,
continuous and scalable API crystallization platform to produce uniform spher-
ical particles. First, emulsion-based crystallization techniques were combined
with droplet microfluidics and off-chip thin film evaporation to produce spher-
ical crystalline agglomerates (SAs) of a model API compound with unprece-
dented uniformity. Not only did this setup overcome the typical problem asso-
ciated with batch emulsion crystallization, the polydispersity of the SAs, but it
also circumvented the issue of clogging, a typical microfluidic crystallization
problem. In addition, on-line microscopic monitoring enabled the observation
of the distinct phases of crystallization: droplet shrinkage, stochastic nucleation,
spherulitic growth, and agglomerate aging - a solvent-mediated phase transfor-
mation process.
Next, the effect of operating conditions (temperature, droplet size, rate of
srhinkage) on the morphological outcome of thin-film spherical crystallization
from monodisperse emulsions was investigated through experiments and math-
ematical modeling. It was determined that spherulitic crystal growth [193] is
required to form SAs of a reliable quality, which can only be achieved if a crit-
ical supersaturation is attained within a droplet before nucleation occurs. This
scenario was modeled by using the classical nucleation theory [22] in conjunc-
tion with a theory for nucleation in small volumes with time-varying supersat-
uration [169] to obtain P0(ts), the probability of no nucleation occurring within
a single droplet before attaining critical supersaturation. This calculated prob-
ability was compared to fI , the experimentally observed fraction of complete
SAs among the ensemble. The experimental trends were accurately captured by
the simulations.
Subsequently, prototypes of a continuous thin-film evaporator were built to
complement continuous microfluidic emulsion generation. These prototypes
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were capable of producing SAs of good quality at rates on the order of 1-10
g/day. As the second prototype has a volumetric footprint of only ∼10 L, scaling
the process to industrially relevant rates by parallelization is straightforward.
Finally, future research opportunities opened up by this thesis were de-
scribed. These include advanced spherical formulation techniques enabled by
microfluidics, the industrial implementation of the developed continuous crys-
tallization process, and the use of monodisperse microfluidic emulsions for the
fundamental investigation of spherical crystallization.
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A Supporting Information for Chapter 2
A.1 Fabrication of Capillary Microfluidic Devices
A schematic of the assembly and a photograph of the capillary microfluidic
devices used in our experiments is provided in Figure 30. Square (ID=1 mm)
and round (ID=0.8 mm, OD=1 mm) borosilicate capillaries were purchased
from VitroCom Inc. A micropipette puller (Sutter Instruments P-97) was used
to pull the round capillaries. Pulled capillaries were broken manually to pro-
duce tapered capillaries with different nozzle diameters. The capillaries were all
functionalized with Trichloro-(1H,1H,2H,2H-perfluorooctyl)-silane under vac-
uum for 8 hours in order to render their surfaces hydrophobic. Teflon tubing
(VICI, OD=1/16 in, ID=0.01 in) was used to connect the capillary device to the
syringes containing the continuous and dispersed phases (CP and DP, respec-
tively). The same were used as outlets. Silicone rubber transition tubes (Saint
Gobain, ID=1 mm, OD=3 mm) were used to connect the inlets to the square
capillaries. Fittings were purchased from Upchurch Scientific. DEVCON 5 min
Epoxy was used to seal the connection between the square capillaries and the
transition tubes.
A.2 Droplet Breakup
Figures 31, 32, 33, and 34 show droplet breakup images taken at 200 frames
per second under the four conditions shown in the paper. As mentioned above,
manually broken capillaries were used. Although it would be desirable to work
with perfectly regular tips, droplet breakup was sufficiently reliable for our
work, as confirmed by subsequent size distribution measurements on droplets.
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Figure 30: Schematic and photograph of a capillary microfluidic device used
in our experiments. A tapered round capillary (OD=1 mm) is inserted into a
square capillary (ID=1 mm). The two ends of the square capillary function as
inlets, and the round capillary functions as a collection tube/outlet. Silicone
rubber transition tubes are used to connect the capillaries to the standard Teflon
microfluidic tubing connected to the syringe pumps (not shown on figure).
Figure 31: Droplet breakup in the narrow device at QCP =100 µL/min, QDP=20
µL/min. Droplet diameter was measured to be 80 µm with a standard deviation
of ∼1%.
Figure 32: Droplet breakup in the narrow device at QCP =100 µL/min, QDP=30
µL/min. Droplet diameter was measured to be 115 µmwith a standard deviation
of ∼1%.
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Figure 33: Droplet breakup in the wide device at QCP =1000 µL/min, QDP=20
µL/min. Droplet diameter was measured to be 210 µmwith a standard deviation
of ∼1%.
Figure 34: Droplet breakup in the wide device at QCP =1000 µL/min, QDP=40
µL/min. Droplet diameter was measured to be 310 µmwith a standard deviation
of ∼1%.
A.3 Observational Evidence of SA-Triggered Nu-
cleation
Figure 35 shows an instance of nucleation triggered by the formation of a
spherical agglomerate in the immediate vicinity of a droplet in a populations of
45 µm SAs under indentical conditions to the one presented in the manuscript.
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Figure 35: Observational evidence of nucleation triggered by an adjacent spher-
ical agglomerate.
A.4 Microscopic Observation of the Aging Phenomenon
Figure 36 shows a series of micrographs for a typical aging event. It can be
seen that the initial agglomerate visibly coarsens from an initially uniform and
smooth (black) optical texture in the matter of a few seconds.
Figure 36: Aging of a ∼50 µm glycine spherical agglomerate.
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B Supporting Information for Chapter 3
B.1 The relationship between film thickness and
shrinkage at a constant temperature
Figure 37 presents an empirical relationship between the effective film thick-
ness he , (defined as h f − d0, where h f is the dispensed film thickness, and d0
is the initial droplet diameter) and the linear shrinkage rate d′ at T =65 ◦C for
all nine experiments at this temperature. It can be seen that as the film thickness
increases, the shrinkage rate decreases with the cube of the film thickness. In
a purely diffusive case, we could expect a linear decrease, which suggests the
presence of a convective enhancement (possibly due to natural convection) in
this system.
Figure 37: An empirical relationship between the effective film thickness he
, (defined as h f − d0, where h f is the dispensed film thickness, and d0 is the
initial droplet diameter) and the linear shrinkage rate d′ at T =65 ◦C for all nine
experiments at this temperature
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B.2 The calculated values of classical nucleation
theory parameters
Table 6 presents the calculated values of CNT parameters at the tempera-
tures used in this study, while Figure 38 shows the parameter B as a function of
continuous phase temperature. Fitted B values were used for modeling.
Table 6: The calculated value of classical nucleation parameters under the tem-
peratures used in this study. #: experiment label (as seen in Table 2 and Table
4); T : heating temperature; TCP : measured continuous phase temperature;
σ : interfacial tension between the nucleus and the crystallizing solution; B :
dimensionless exponent B .
# T TCP σ B
◦C ◦C mJ/m2
10 45 39 12.8 2.69
V3 50 45 12.4 2.28
11, V1 55 48 12.2 2.13
V4 60 52 11.9 1.89
1-9, V5 65 59 11.5 1.59
V6 70 63 11.2 1.44
12, V2 75 68 11.0 1.27
13 85 78 10.5 1.03
B.3 Fitting of the CNT parameter A
B.4 Shrinkage Rate and Temperature
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Figure 38: Parameter B as a function of continuous phase temperature along
with the polynomial fit used for modeling.
Figure 39: Experimentally derived log(A) values as a function of continuous
phase temperature along with the fitted quadratic curve that was used in the
modeling. This fit implies that the relationship is of the form A= A0 exp[ f (T )],
which is consistent with previous reports [24].
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Figure 40: Experimentally measured shrinkage rates at various continuous
phase temperature along with the linear fit used in the simulations for Figure
16d.
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